← All companies

Diploma PLC

DPLM.LLondon Stock Exchange (Main Market, FTSE 100)GBPValue-add specialist distribution (controls, seals, life sciences)Reviewed Nov 15, 2026

Organic value-add distribution plus capped bolt-on acquisitions

8 of 11 research checks complete. Still to complete: Security and evidence base; Opportunities and funded scenarios; Variant view and catalysts · FY2026 (year to 30 September 2026) provisional earning power from H1 actuals plus nine-month guidance; March 2026 balance sheet rolled to September with estimated H2 cash; price 2 November 2026

A decentralised group of niche value-add distributors. Its owner cash comes from small, high-margin businesses that grow organically on very little capital, plus bolt-on purchases at about 8-9x EBIT. Today's earnings include an aerospace-fastener windfall at Peerless that this model does not capitalise at full value.

  • Peerless revenue and margin: spot aerospace fastener pricing versus contract volume
  • Organic growth excluding Peerless versus the 5% financial model
  • Acquisition spend, entry EBIT multiples and the annualised profit of the 15 deals from the last twelve months
  • Working-capital build (inventory) and free-cash-flow conversion
Inspect live quotes, sensitivity grid & cash-flow bridge

Scenario assumptions

Organic value-add distribution plus capped bolt-on acquisitions · FY2026 (year to 30 September 2026) provisional earning power from H1 actuals plus nine-month guidance; March 2026 balance sheet rolled to September with estimated H2 cash; price 2 November 2026

DriverDownsideBaseUpside
Owner cash / new working capital and capex50.0%60.0%90.0%
Exit / after-financing owner cash16.00×22.00×27.00×
Annual share dilution0.0%0.0%0.0%
Surplus offered to deals100.0%100.0%100.0%
Organic revenue growth
Years 1–2: 0.0%
Years 3–5: 2.5%
Year 1: 5.0%
Years 2–5: 5.6%
Years 1–5: 7.5%
Owner-cash margin on organic revenue
Year 1: 17.3%
Years 2–5: 16.3%
Year 1: 18.3%
Year 2: 17.6%
Years 3–5: 17.8%
Year 1: 18.5%
Years 2–5: 18.4%
Price paid per unit of acquired revenue
Years 1–5: 1.99×
Years 1–5: 1.63×
Years 1–5: 1.58×
Owner-cash margin of acquired businesses
Years 1–5: 15.8%
Years 1–5: 15.8%
Years 1–5: 15.8%
Acquired revenue growth after purchase
Years 1–5: 2.5%
Year 1: 4.4%
Years 2–5: 5.1%
Years 1–5: 7.1%
Deal budget (capital available for acquisitions)
Years 1–2: 56.00
Years 3–5: 250.00
Years 1–2: 250.14
Years 3–5: 280.00
Years 1–2: 310.00
Years 3–5: 380.00
  • Downside case. Aerospace fastener supply catches up: Peerless revenue falls about 20% over FY27-FY28 and its margin returns to about 30% (owner-cash margin 17.3% in FY27, 16.3% after); UK and European industrial markets stay weak, so organic revenue is flat for two years, then grows 2.5%. Deals stop to FY25's 56 for two years (a dry spell longer than the record's), then return to 250, at 9.5x EBIT (2.0x revenue), growing 2.5% after purchase. Exit at 16x, near Diploma's trough trailing multiples (18-21x) less a further step for a slower business.
  • Base case. Revenue build from FY26E revenue (1,807.7) at an 18.9% owner-cash margin. Organic revenue grows 5% in FY27 (management's guide back towards its model), then 5.65% (sector rates weighted by revenue). Peerless's spot-price margin fades from 54% to 47% in FY27 and 40% in FY28 on 9% volume growth, taking the owner-cash margin to 17.6%; mix then lifts it towards 18.0%. Deal budget 250 a year in FY27-FY28 (the FY21-FY25 average), 280 in FY29-FY31 and 320 after; bought at 1.63x revenue (a 21% operating margin at the last 15 deals' 12.9% entry yield) and growing at the non-Peerless rate (4.4%, then 5.1%); about half a year's profit arrives in the purchase year; retained cash saves facility interest; new capital at an 0.6 owner-cash return. Exit at 22x after-financing owner cash.
  • Upside case. Structural end markets (aerospace build backlog, defence, datacentres, energy) keep organic revenue growth at 7.5%, near the seven-year record; Peerless eases only to 47-50%, so the owner-cash margin stays about 18.4-18.7%.

Research notebook

Reviewed Nov 15, 2026

8 of 11 research checks complete. Still to complete: Security and evidence base; Opportunities and funded scenarios; Variant view and catalysts
Business model

Researched 3 November 2026 from Diploma's filings and free market data, as a blind test of the pipeline. Money is GBP millions unless stated. Source IDs refer to sources/registry.json; fact IDs to financials/facts.json.

Evidence plan

What we are buying: one class of 5p ordinary shares listed in London (FTSE 100), 134.3m in issue, no controlling holder (largest notified holder Capital Group 12.96%). The fiscal year ends 30 September. FY26 results are due on 17 November 2026, two weeks after this study, so FY26 figures here are estimates from H1 actuals and the 16 July guidance.

QuestionEvidence usedWhat it cannot settle
Group economics, capital, cashFY21-FY25 results and annual reports, five-year records back to FY16, H1 FY26 interimBusiness-level P&Ls; Diploma reports three sectors only
Acquisition economicsAcquisition notes (price, net assets, pro forma revenue and profit) FY21-H1 FY26; Peerless announcementPost-acquisition results by deal, except Peerless indirectly
Peerless (largest profit driver)Peerless announcement (pre-acquisition P&L), FY24 note 11, AR2025 sector mix, H1 FY26 sector data, Q3 callIts current revenue and margin, which are bounded estimates here
Demand and cycleSector reviews, organic growth by year, issuer statements on aerospace backlog, datacentres, defenceIndependent industry volume data; no paid aerospace or construction databases were used
Competition and counterpartiesIssuer risk disclosures, sector reviews, peer trailing multiplesSupplier contracts, customer interviews, competitor private accounts
ManagementRemuneration report, PDMR notices, AR governance sectionsReferences from former employees or counterparties

No fieldwork was done: no interviews with customers, suppliers, former employees or competitors, and no site visits. Statements by management are evidence of what management says, not independent confirmation. The parent session holds an investor's result for Diploma; it was not opened.

Value-creation mechanism

Diploma owns about 40 small specialist distributors (with some light manufacturing, kitting and machining) that sell critical, low-cost-to-the-customer parts: aerospace fasteners, seals, cable, connectors, diagnostic consumables. The customer pays for availability, traceability, technical help and speed, not for the part, so gross margins are about 47% and operating margins 20-25% on very little capital. The repeatable mechanism has two steps. First, each business grows organically while needing only about 20p of working capital per £1 of new revenue, so organic growth earns roughly 80p of owner cash per £1 of new capital. Second, the group buys more such niches at about 8-9x EBIT, leaves them decentralised, and lets them compound inside the group. Most value is created by the first step: the measured FY21-FY25 achieved deal yield is about 13% pre-tax (about 10% after tax), close to Diploma's own post-tax discount rate (9.3-9.8%, FY25 note 10), while the organic step earns far above any cost of capital. Acquisitions matter because they add more growing niches to compound, not because they are bought cheaply. In FY24-FY26 one purchase, Peerless, earned a windfall from an aerospace fastener shortage that management did not underwrite.

Business-model profile

Comparable firms are chosen by these traits, not by the industry label.

Growth vehicle: Mixed: organic and acquisitions. Revenue rose from 538.4 in FY2020 to 1,524.5 in FY2025 (2.83×); organic growth alone compounded to 1.64× over the same years, so acquisitions supplied the other 1.73×, roughly half of the growth each. Acquisition cash was 14.6% of revenue over FY2023–FY2025. Both vehicles earn their own return: organic growth needs about 20p of working capital per £1 of new revenue, while deals achieved about 13% pre-tax. The model forecasts organic and acquired revenue separately, each with its own capital cost.

Capital intensity: 1.4% of sales, asset-light. Capital spending on PP&E and software is about 1.4% of revenue over FY2023–FY2025 (14.4 in FY25, 0.96× depreciation): warehouses and IT for value-added distribution. Growth consumes working capital instead (18.4% of revenue, 134 inventory days) and acquisition cash (14.6% of revenue over FY2023–FY2025), so capex understates what growth costs.

Comparables. A comparable firm distributes specialized, low-cost but critical consumables and components to fragmented industrial and healthcare customers, holds inventory for availability, grows both organically and by regular bolt-on acquisitions, and needs little fixed capital. Matching traits: mixed growth vehicle, asset-light, working-capital-funded growth. Not the label: "Industrial distributor" suggests thin-margin, cyclical volume wholesale; Diploma earns a 22.5% operating margin from service and availability on small-ticket parts.

Declared in valuation/model.json (businessProfile). npm run check measures deal and capital intensity from the reported facts, and the outside view grades the forecast only against firms that share them.

Economic snapshot

FY25 (year to 30 September 2025), adjusted figures, statutory balance sheet (fact IDs in brackets).

MeasureValueDefinition
Revenue (revenue2025)1,524.5
Gross margin46.7%1 - cost of inventories sold 812.7 / revenue
Adjusted operating margin22.5%before acquisition amortisation and deal costs
Incremental margin35.8% (FY25), 29.4% (FY24)change in adjusted operating profit / change in revenue
Trade working capital281.1 (18.4% of revenue)inventories 297.4 + receivables 229.0 - payables 245.3
PP&E / right-of-use assets66.7 / 76.1
Tangible capital incl. leases423.9trade working capital + PP&E + ROU
Return on tangible capital, after tax60.6%342.7 x 0.75 / 423.9 (leases capitalised)
Return on capital employed, after tax73.1%(342.7 - 3.9 lease interest) x 0.75 / 347.8 (leases expensed)
Return incl. goodwill and acquisition intangibles17.5% after tax342.7 x 0.75 / (423.9 + 563.5 + 479.1)
Issuer ROATCE (pre-tax)20.9%pro forma profit / capital incl. goodwill and past amortisation (note 15.6)
Inventory / receivable / payable days134 / 55 / 110on cost of sales, revenue, cost of sales
Capex / depreciation0.96x14.4 capex vs 15.0 PP&E and software depreciation; c.1% of revenue
Net debt / covenant EBITDA299.4 / 360.6 = 0.8xexcludes leases (83.8)
Excess cashnone81.7 cash sits inside a revolving facility

Normalisation before returns: capex was close to depreciation over FY23-FY25 (net capex 21.6, 14.0, 13.1 against depreciation of a similar size), so no capex adjustment; minorities are tiny (0.6); acquisitions are consolidated at their own margins with pro forma annualisation in ROATCE. The material normalisation is Peerless (below): about £17m of FY25 profit and about £34m of FY26E profit above a 40% through-cycle margin. Trailing to March 2026: revenue 1,647.1, adjusted operating profit 394.7 (24.0%), trade working capital 353.5 (21.5% of trailing revenue, up because of inventory bought for growth and Middle East supply risk).

Economic segmentation

Reported sectors (FY25): Controls 55% of revenue / 65% of sector profit (30.0% margin), Seals 30% / 23% (19.3%), Life Sciences 15% / 12% (19.5%); corporate costs 41.3. Revenue share understates where the profit sits. Re-cut by how value is created (FY25, pre-corporate sector profit 384.0; estimates bounded from sector data and the AR2025 business mix):

Economic unitEst. revenueEst. profitProfit shareDemand driverCharacter
Peerless (US/EU aerospace fasteners)c.196c.96 (49%)c.25%aircraft build rates, MRO, fastener supply shortagestructural demand, cyclical windfall margin
Other aerospace and defence interconnect and fasteners (Clarendon, IS Group, Swift, Spring; CDM from June 2026)c.350c.85c.22%aerospace, European defence, energystructural growth, some cyclicality
Windy City Wire (US low-voltage cable)c.307c.70c.18%commercial construction, datacentres (c.15% of WCW)cyclical construction with share gains
Seals aftermarket and OEM (Hercules, R&G, DICSA, M Seals, DAS)4568823%repair of installed equipment (replacement), OEM buildsmostly replacement; UK/Australia weak
Life Sciences (Canada, ANZ, UK/Ireland, Nordics)2324512%procedure and test volumes, supplier agency agreementsdefensive, supplier-dependence risk

Method: Controls excluding Peerless earned 24.2% in FY24 (169.9 - 25.0 Peerless post-close profit, over 652.4 - 54.1). Holding that margin in FY25 leaves Peerless with about 95.6 of the 250.6 Controls profit on about 196 revenue (23% of pro forma Controls revenue, AR2025 p.23): a 49% margin, against c.30% when Diploma bought it (FY to Sep 2023 EBIT USD33.5m on USD107.7m). The split of the remaining Controls profit between WCW and the rest uses the same margin and is illustrative only.

Two conclusions. About 25% of FY25 sector profit (and more in FY26E, about 27% of group profit) comes from one business on 13% of revenue, earning a margin the business never earned before 2024. And half the portfolio's profit is tied to aerospace, defence and datacentres, which explains both the recent acceleration and the elevated multiple.

Unit economics

The unit through which Diploma adds capacity is the acquired niche business. Three disclosed units, in absolute money (acquisition notes):

Alpha Labs (UK IVD, Jul 2025)Swift Aerospace (Dec 2025)Peerless (May 2024)
Price (net of cash)27.519.1243.3
Revenue (pro forma annual)22.9c.26.6 (13.3 for six months)129.9 (FY24); USD107.7m before purchase
Operating profit4.7 (20.5%)c.4.6 (2.3 for six months, 17%)59.9 (46%) in FY24; USD33.5m (31%) before purchase
Net tangible assets acquired10.2 (inventory 3.0, receivables 3.3, payables -3.1, PP&E 5.0, investment 1.2)8.3 (inventory 8.8)63.5 (inventory 65.6)
Pre-tax return on tangible capital46%c.55%94% (FY24)
Pre-tax yield on price17.1% (5.9x)c.24% on the six-month run-rate, doubled (4.2x)14% on the purchase underwriting (c.7x); 39% on FY25E profit

A representative bolt-on therefore looks like this (illustrative, built from the disclosed units and group ratios): revenue 25, gross profit 11.5 (46%), staff 4.0, occupancy and other costs 2.0, an allocated share of central cost 0.5 (central cost is about 2.7% of revenue and largely fixed), operating profit 5.0 (20%). Tangible capital is about 5.5 of working capital and 1.0 of PP&E, so tax at 25% leaves 3.75 of NOPAT on 6.5 of tangible capital (58%). Bought at 8x EBIT (40), it yields 9.4% after tax at entry. If it then grows 6% a year at constant margin, needing about 21p of working capital per £1 of new revenue, profit is about 6.7 after five years and the cumulative return on price plus added working capital rises to about 12% after tax.

The comparison that matters is before and after Diploma. The evidence of an operating uplift is mixed. Diploma claims sales excellence, scaling investment (new facilities in the Czech Republic and Germany), cross-selling and leadership development. Measurable cases: DICSA, R&G and T.I.E. needed new leadership after purchase; Peerless's margin rose from 31% to about 49% within a year, but management attributes that to "positive tailwinds and share gains in the aerospace market" (FY24 results), not to group levers. Diploma does not centralise purchasing, so there is no TerraVest-style buying-power lever. The honest reading is that Diploma's lever is capital and patient ownership plus selective investment, which keeps good niches growing; it is not a restructuring machine.

Failure case: T.I.E. (US industrial automation repair), bought March 2023 for 75.1 at a pro forma 6.9 of profit (10.9x EBIT). The FY25 Controls review says it had "more challenging performance since its acquisition in 2023, reflecting softness across automation markets", and a new leadership team was formed in late FY25. R&G (UK fluid power, 99.1 in 2022, plus four bolt-ons in FY24) has been weak since, hit by UK construction, oil and gas and agriculture. Both show the limit of the model: a niche distributor follows its end market, and decentralised ownership cannot create demand.

Growth capacity inside a unit: Diploma's organic investment is mainly inventory and receivables, not capacity. Stage 6 measures the group-level organic return (about 0.8 of owner cash per £1 of new working capital and capex).

Independent checks

  1. Unit model against group accounts. The representative unit's ratios (46% gross, 20-24% operating margin, about 20% working capital) match the group (46.7%, 22.5%, 18.4%; 21.5% at March 2026). The group's after-tax return on tangible capital (61%) is consistent with the unit's 58%. Goodwill-inclusive after-tax returns (17.5%) sit well above the deal-level after-tax entry yields (8-10%), as expected when the group includes decades-old, fully grown businesses bought cheaply or started in-house.
  2. Acquisition record against group profit growth. FY20-FY25 adjusted operating profit rose from 87.1 to 342.7. Organic revenue growth compounded to 1.637x. Even with all margin expansion credited to the base business, acquisitions explain at least 127.6 of FY25 profit (after removing the Peerless windfall) on 1,209.4 of matched deal capital, a 10.6% pre-tax floor. The high bound (base held at its FY20 margin) is 15.1%. Entry yields disclosed at the time (FY24 deals "6x", FY25 "8x", LTM "8x", latest seven "9x") sit inside this range. See valuation/calculations.json (dealYieldLow/Mid/High).
  3. Peerless allocation, adverse test. If Controls excluding Peerless had in fact risen to 25% in FY25, Peerless's FY25 profit falls to about 91 (46%) instead of 95.6; at 24% it is about 97 (49%). Every plausible allocation gives Peerless 46-49% in FY25 and above 50% in H1 FY26, against 30% before purchase. The conclusion that a large windfall sits in current earnings survives the adverse allocation.
  4. Peer cross-check. Large broadline distributors earn much lower margins (Bunzl, RS Group and Wesco trade at 19-23x statutory trailing earnings). The high-margin specialist peers (Fastenal 43x, Grainger 35x) earn mid-teens to 20% margins on far larger, more commoditised ranges. Diploma's 22-27% margins put it at the specialist end, consistent with the value-add service model rather than scale purchasing.

Where the consensus may disagree: the market and management treat FY26's 26.5% margin and 20%+ ROATCE as evidence of a better business; this study treats about 2 points of that margin (34 of profit on about 1,800 of revenue) as a supply-shortage windfall at one business. The observation that would settle it is Peerless's margin as aerospace fastener supply catches up with build rates; management has already said it is "easing off the margin" (Q3 call).

History, market & cycle

Consistent history: fiscal years to 30 September; issuer organic growth is at constant currency and includes acquired businesses' growth after their first year of ownership. FY20-FY25 revenue rose 2.83x: organic 1.637x, the rest acquisitions net of disposals and currency (FY24 -3%, FY25 -2% from currency).

Demand drivers and cycle

Who decides. The end user is an engineer or technician (an aerospace subcontractor's buyer, an MRO shop, a hydraulic repair shop, a hospital lab). The payer is that business. The decision-maker is often the engineer who specifies the part or the buyer who needs it today; price matters less than availability and certification because the part is a small share of the customer's cost (fasteners are up to 5% of aircraft build value, but each fastener is trivial; Peerless announcement p.1). Diploma's pitch is therefore service: kitting, traceability, vendor-managed inventory, same-day delivery.

Demand split (judgment from sector disclosures).

PartShare of profit (est.)MechanismCyclicality
Replacement / MRO / consumablesc.45%seals and fluid-power repair (Hercules Aftermarket two-thirds online), lab and diagnostic consumables, aerospace MROlow
Growth capex and new buildsc.40%aircraft builds, defence programmes, datacentre and commercial construction cabling, OEM sealsmedium to high
Regulation-drivenc.5%aerospace certification and traceability, medical device rules (raise barriers rather than volume)low
Spot-shortage premiumc.10%Peerless spot pricing while fastener manufacturers cannot meet demandhigh, reverses

The cycle, measured. Organic revenue growth: FY20 -7% (underlying, Covid), FY21 +12%, FY22 +15% (inflation and reopening), FY23 +8%, FY24 +6%, FY25 +11%, H1 FY26 +15%, nine months FY26 +15%. Operating margin: FY16-FY19 17.2-17.8%, FY20 16.2% at the trough, then 18.9%, 18.9%, 19.7%, 20.9%, 22.5% and 24.5% in H1 FY26 (26.5% guided for FY26). The portfolio has not had a revenue decline outside Covid in the ten years reviewed; the FY20 trough cost 10% of operating profit (97.2 to 87.1). Seals and Life Sciences have been flat to low growth since FY24, so recent group growth is Controls (FY25 +20% organic, H1 FY26 +26%).

Market misperception to test. The market reads FY25-FY26 as a structural step-up ("sustainable quality compounding", management's phrase). The competing explanation is a supply shortage in aerospace fasteners: Peerless's margin went from c.30% to about 49% within a year of purchase and above 50% in H1 FY26, while the rest of Controls stayed around 24%. Management's own March 2026 language ("aerospace demand and supply characteristics are favourable") and July comments ("taking a little bit of the heat out of some of the spot pricing", growth moderating "back towards that 10%ish") support the shortage reading. The series that would distinguish them is Peerless's margin and Controls organic growth as aircraft build rates rise and fastener manufacturers add capacity; neither is disclosed directly, so stage 11 freezes a check on the Controls margin.

Competition

Competition happens locally and by niche, not across Diploma as a whole.

  • Aerospace fasteners (Peerless, Clarendon, Swift). Peerless says it is "one of the largest independent value-added distributors" in a "ca. $7 billion, highly fragmented" market (announcement p.1). Competitors are the large aerospace distributors and the manufacturers' own direct channels. The advantage is approved-supplier status with all major primes and about 80 subcontractors, inventory breadth (Peerless inventory 65.6 on 130 of revenue at purchase) and traceability. The competitor who could hurt it is a fastener manufacturer that chooses to sell direct to subcontractors once capacity is ample, or a larger distributor bidding for contract volume as spot premiums fade.
  • US low-voltage cable (WCW). Competes against national electrical distributors on specification (being written into datacentre and building designs), service and inventory. WCW has grown 17% a year on average since its 2020 acquisition (H1 FY26 p.7) and sources copper 100% in the US. Construction cycles and copper prices pass through.
  • Seals and fluid power. Fragmented regional markets. Hercules competes on breadth and e-commerce in US repair; R&G and DAS face weak UK and Australian markets.
  • Life Sciences. Diploma distributes other companies' devices and diagnostics under agency agreements in Canada, Australia/New Zealand, the UK, Ireland and the Nordics. Competitors are other local distributors and the manufacturers' own subsidiaries.

The number of competitors in Diploma's niches is not disclosed; private-equity buyers of distributors are the main competitors for acquisitions (H1 FY26 deals cost about 6x annualised profit, Q3 deals about 10x).

One-sentence advantage: Diploma's niches win on availability and technical service for parts whose failure is costly and whose price is minor, and the evidence that this is durable is ten years of 16-26% operating margins across varied end markets, including the Covid trough (five-year records FY16-FY25 and FY26 guidance), not any single scale advantage.

Counterparty incentives

CounterpartyWhat they wantWhat Diploma gives themTheir outside optionWhat would make them change
Aerospace fastener manufacturers (supplying Peerless)full factories, broad reach to subcontractors without carrying small ordersa channel to about 80 subcontractors, kitting and inventory risk on small lotssell direct or through other distributorsample capacity after the shortage: they may take spot volume direct or squeeze distributor margins
Aerospace primes and subcontractorson-time, certified parts; no line stoppagesinventory, traceability, VMIdirect supply or other distributorsa normalised supply market lets them re-tender and push price
Life Sciences principals (device and diagnostics makers)market access in small countries without building a subsidiarylocal sales, service and regulatory workset up their own subsidiary or switch distributoronce a market is large enough, disintermediation; the Nordics business lost a key supplier in FY25
Datacentre and building contractors (WCW)specified cable delivered to site on timestock, cut-to-length, specification supportnational electrical distributorsweaker construction or a cheaper rival written into the specification
Vendors of acquired businessesa home that keeps their name, staff and autonomy; a fair pricedecentralised ownership; some founders stay (DAS founder led six years under Diploma)private equity, trade buyersa better price elsewhere; Diploma walks away from many deals (FY25)
Lenders (USPP, RCF)covenant safety (3.5x)leverage 0.8x, fixed-rate notes to 2036—not a binding constraint at current leverage

Dependence runs both ways. Distributors exist because manufacturers and principals do not want small, scattered customers; the risk is concentrated where a market becomes big enough to serve directly, which the AR2025 risk register names ("a key supplier revokes a supply agreement and access the market through a competitor or directly"). The Peerless windfall is the clearest counterparty-driven exposure: its margins depend on fastener manufacturers being unable to serve demand.

Headlines and management statements about these counterparties are evidence of actions and of management's view, not of the counterparties' motives; no supplier or customer was interviewed.

Management & incentives

The capital allocators are the CEO, Johnny Thomson (since 2019), the CFO, Wilson Ng (board member from August 2025, formerly Group Financial Controller), and the board chaired by David Lowden. Acquisitions are sourced and run largely by sector and business leaders under group approval. Sources: AR2025 remuneration report pp.81, 89, 92-93; directors' report p.98; PDMR notice 16 January 2026 (dplm-pdmr-jan26).

Ownership and incentives

PersonRoleShares (latest)Options / awardsFY25 payDealings
Johnny ThomsonCEO since 2019196,483 at 30 Sep 2025; 208,500 after the January 2026 sale79,424 vested nil-cost options (exercised Nov 2025); unvested PSP 2023 73,608, PSP 2024 61,091, PSP 2025 55,213 (granted Nov 2025 at 5,390p)£7.15m single figure: salary £918k, bonus £1.84m (100% of max), PSP £4.33mExercised 57,007 options Nov 2024 at 4,536p (26,794 withheld for tax); sold 30,000 at about 5,668p on 16 Jan 2026
Wilson NgCFO (board from 14 Aug 2025)none at 30 Sep 20259,433 vested, 12,856 unvested£0.66m (part year)50% of bonus deferred into shares until 250% of salary is held
Chris Daviesformer CFO, resigned 13 Aug 2025 "with immediate effect"7,741 held under post-cessation rules2022-2024 awards lapsedno bonus, no payment in lieu of notice—
Non-executivesseven, incl. Chair David Lowden (£365k fee)not materialnone£49k-£84k each—

The CEO's stake is about £15.1m at 7,265p, plus about £13.8m of unvested performance shares. If the shares compound at 8% a year for five years, his owned stake gains about £7.1m, roughly one year of his FY25 pay. His interests are therefore broadly but not overwhelmingly aligned with shareholders': pay is of the same order as the gain on his holding. He meets his 300% shareholding requirement (1,389% of salary at September 2025). He took a non-executive advisory role at TDR Capital, a private-equity firm (AR2025 nomination report).

Incentive metrics:

  • Annual bonus (max 200% of salary): 50% adjusted operating profit, 20% revenue, 25% free cash flow, 5% engagement. FY25 targets (on-target 308.1 profit, 1,436.8 revenue, 201.5 FCF) were beaten (342.2, 1,524.5, 247.2), paying 100%. No return-on-capital metric in the bonus.
  • PSP (300% of salary for the CEO): 75% adjusted EPS growth (25% vesting at 5% a year, 100% at 13% a year, over three years) with a ROATCE underpin; 25% total shareholder return against the FTSE 100.

What the targets imply: the 2025 PSP vests in full if adjusted EPS reaches 176.0p x 1.13^3 = 254p in FY28. FY26E adjusted EPS is already about 254p (479 of operating profit less 23 of interest, taxed at 25%, over 134.3m shares), largely because of the Peerless windfall. Even on the normalised earnings in this model (about 235p), only about 4% a year growth is needed to FY28. The EPS metric rewards acquisitions funded by debt at 5% (any deal above about a 7% pre-tax yield is accretive) with only the ROATCE underpin as a return guard.

Track record and references

MeasureUnder Thomson (FY19-FY25)
Revenue544.7 → 1,524.5 (2.8x)
Adjusted operating profit97.2 → 342.7 (3.5x)
Adjusted EPS64.3p → 176.0p (18% a year)
Sharesabout 113m → 134.3m (+19%, equity raises of 189.8 in FY20 and 231.9 in FY23)
Operating margin17.8% → 22.5% (FY26 guided 26.5%)
ROATCE (issuer)19.1% (FY20) → 17.3-18.1% (FY22-FY23) → 20.9% (FY25)
Deals57 since 2019 for £1.6bn (H1 FY26 p.5), "collectively generating returns over 20%" on the issuer's pre-tax ROATCE basis
TSR119% over the three years to September 2025 (91st percentile of the FTSE 250 comparator)

Measured, not quoted: the FY21-FY25 achieved deal yield is 10.6-15.1% pre-tax (stage 6), below the "over 20%" claim, which includes the organic growth of businesses after purchase and is measured on pre-tax ROATCE. ROATCE fell while big deals were absorbed (FY21-FY23) and rose when deal spend paused (FY25: 29.6 net), as the CFO's review itself says.

Decisions that failed or under-delivered: T.I.E. (2023, automation downturn, leadership replaced), R&G (2022, UK markets), Life Sciences Nordics (key supplier lost, FY25). Disposals: nine in five years at about 6x, including Kubo, Pennine and Gremtek (FY25 proceeds 46.6, gain 17.3).

Price awareness: the CEO sold 30,000 shares at about 5,668p in January 2026, after the November 2025 vesting; the price is now 7,265p. A partial sale after a vesting is normal and not a signal.

References and bench: no independent references (former employees, counterparties) were collected here. Bench signals from filings: an internal CFO succession in 2025, new sector HR roles, a first graduate programme, leadership changes at DICSA, T.I.E. and Diploma Australia Seals, and founders retained after purchase (Peerless's Bill Way and Don Russo; DAS's founder for six years). Key-person risk sits with Thomson, who has led the strategy since 2019.

Capital allocation principles

Tested against the five principles (Mauboussin and Callahan pp.52-54). Sources: FY21-FY25 preliminary results (CEO reviews, funds flow, cash flow statements, EPS and disposal notes); AR2025 remuneration policy (PDF p.89). Investment rates are in 04-capital-allocation.md.

PrincipleVerdictDecision used as evidence
1. Zero-based allocationPartlyCapital moved to new platforms rather than incumbents: about 96% of FY21-FY25 growth investment was deals (1,224 of 1,273), and the three largest went to US platforms in cable (WCW 347.7) and aerospace fasteners (Peerless 243.3; CDM about 127 in FY26). Nine businesses worth 104.5 were sold, including a1-CBISS to its largest supplier (FY21, 12.0), Kentek, the Russian filters business (November 2021, 10.0), and Hawco as "lower growth, lower margin" (FY23, 24.5). The limit: "We don't divest due to underperformance – we see that as our job to resolve" (FY25 prelim p.10). Disposals test strategic fit, not returns, so T.I.E. and the Nordics keep their capital while being fixed.
2. Funding strategies, not projectsPassThe group funds platform-plus-bolt-on strategies: WCW, DICSA and T.I.E. were bought as "strategic platform acquisitions" (FY23), and R&G added two bolt-ons for 5 straight after purchase (FY22). Group capital follows the sector strategy: FY22 Healthcare field equipment (6.8, "directly supports revenue growth") and the FY23 capex step-up to scale Shoal, Hercules Aftermarket and R&G. The financial model sets group outcomes and states "what is most important is the return each business generates", so businesses holding more inventory must earn higher margins (FY25 prelim p.9). No project-by-project capital budget is disclosed.
3. Capital is accessible but has a costMostlyEquity was not treated as free: the two placings (September 2020, 193.7 gross for about 10%; March 2023, 9.35m shares at 2,525p, 7.5%) were each tied to a named deal programme (WCW; DICSA and T.I.E.). Share compensation is settled from the EBT, which buys shares in the market (2.8 FY22, 1.9 FY23, 2.3 FY24, 4.1 FY25), and the issuer's free cash flow deducts those purchases. Net of the placings the share count is flat (weighted 124.47m→124.53m FY21-FY22; 134.02m→134.08m FY24-FY25), so awards (expense 22.0 over FY21-FY25) do not dilute. Weakness: the hurdle is pre-tax ROATCE and incentives pay on adjusted EPS, so debt-funded deals look accretive above about a 7% pre-tax yield, below the 9.3-9.8% post-tax discount rates the company itself uses.
4. Zero tolerance for bad growthPartlyManagement did shrink when prices were wrong: FY25 net deal spend fell to 29.6 because "we walked away from a lot of deals" (FY25 prelim p.10), at the cost of a lower M&A contribution that year. It sold lower-margin, lower-growth units, and sold Kentek before the 2022 invasion. But "delivering a Group return on capital of over 20% is not our goal", because high teens "reflects the right level of disciplined investment for growth" (FY25 prelim p.10). That accepts more deals at lower returns, which is sound only while new deals earn their cost of capital. On matched definitions they earned about that, not more: 9.6% after tax.
5. Price versus valueMixedEquity was issued when it was dear relative to what it bought: about 1,700p (derived; about 30x trailing adjusted EPS of 56.4p) in 2020 and 2,525p (23.5x FY22's 107.5p) in 2023, to buy businesses at about 8x EBIT, roughly 11x after-tax cash. Adjusted EPS then compounded at 18% a year. Measured against later value, though, about 20.7m new shares (about 15% of today's count) were sold at a quarter to a third of today's 7,265p. There have been no buybacks, even at the 4,970p 52-week low: at 28-41x adjusted earnings, a buyback yields less than the roughly 9.6% after-tax yield deals achieved, so not buying is consistent with knowing price against value. Deal prices show the same awareness (bolt-ons under 5x in FY23, 6x in FY24 and FY25, nine disposals at about 6x), but prices are rising: the last seven deals averaged about 9x and CDM about 10x.

Governing objective. Stated as "sustainable quality compounding": double-digit adjusted EPS growth, high-teens ROATCE, 90% cash conversion, leverage below 2x and a 5% progressive dividend (FY25 financial model). The targets are per share, and the record mostly matches. Equity was raised only for specific deals at accretive prices, award dilution is neutralised, leverage stayed below policy, and deals were refused when prices rose (FY25). Two features point towards size rather than value per share. The return measure excludes amortisation and deal costs and is pre-tax. And management deliberately trades a higher return for more deployment. The matched deal yield (12.8% pre-tax, 9.6% after tax) is about Diploma's own cost of capital, so per-share value since 2019 has come mainly from capital-light organic growth on acquired niches, not from the deals themselves. Verdict: management behaves largely as if long-term value per share is the goal, with a size bias from EPS-weighted pay that the FY25 pause shows it can resist.

Integrity and governance

  • Adjustments. Adjusted profit excludes acquisition amortisation (61.7), deal expenses (4.0), deferred remuneration to vendors (4.9), inventory fair-value unwind (5.7) and disposal gains (17.3) in FY25. These are standard for acquirers; deferred vendor remuneration and fees are real deal costs, so this study treats them as part of all-in acquisition capital rather than ignoring them. FY25 statutory operating profit (283.7) was 83% of adjusted. The remuneration committee applied no discretion to the formulaic outcomes.
  • CFO departure. Chris Davies resigned in August 2025. The annual report attributes it to personal conduct at a company event; the chair says it was unrelated to financial performance (AR2025 pp.5, 71, dplm-ar25). These are issuer explanations, not an independent clearance of controls. He received no bonus or payment in lieu of notice and his unvested awards lapsed. The previous claim that the annual report supplied no explanation was wrong. No separate cash penalty was included for that premise, so correcting it leaves the financial paths and probabilities unchanged. Correction and impact audit.
  • Board. Independent chair and a majority of independent non-executives; fees rose 6% and the CEO's salary 8% for FY26. Shareholders are institutional (Capital Group 12.96%, an LLC holder 5.27%, BlackRock 5.02%, Norges Bank 3.01%); no controlling holder or related-party transactions of note.
  • Capital discipline signals. FY25 deal spend fell to 56.1 gross when "we walked away from a lot of deals"; leverage policy <2x (covenant 3.5x) has been kept, and equity was raised rather than over-borrowing for large deals.
  • Agency cost: control of resources. Pay grows with size. The bonus pays 50% on adjusted operating profit and 20% on revenue, and the PSP 75% on adjusted EPS, all of which acquisitions raise. A revenue metric rewards size for its own sake. Guards: the ROATCE underpin, 25% relative TSR, the <2x leverage policy and the FY25 deal pause. Moderate cost.
  • Agency cost: risk tolerance. The CEO owns about £15m of shares and holds about £14m of unvested awards, against about £7m of annual pay, so his wealth is concentrated in Diploma. That may make him more cautious than diversified owners: equity rather than debt for WCW and the 2023 deals, leverage of 0.8x against the 2x policy. The likely cost is mild under-leverage, not excessive risk.
  • Agency cost: time horizon. The PSP measures over three years, shorter than a deal's payback, but vested shares (net of tax) must be held until the fifth anniversary of grant. Half of the shareholding requirement continues for two years after departure, and half of the bonus is deferred into shares until 250% of salary is held (AR2025 remuneration policy, PDF p.89). Low cost.
  • Buybacks against share compensation. There are no buybacks. The EBT buys shares in the market to settle awards (2.8, 1.9, 2.3 and 4.1 in FY22-FY25, against share-based expense of 22.0 over FY21-FY25), and the weighted share count excluding placings has stayed flat. The issuer's free cash flow deducts the EBT purchases, so share compensation is treated as a cash cost rather than hidden in financing. All dilution since 2019 came from the two placings.

Agency cost: modest. The main one is incentive design that pays on EPS growth already secured by a windfall and does not weight returns; the valuation treats it through the deal-yield and exit-multiple assumptions (no premium for management quality beyond the measured record) rather than a separate deduction. The CEO's TDR Capital role is a time and conflict question to watch, since TDR is a possible bidder for distribution assets.

Capital allocation

GBP millions. Sources: five-year records (AR2025 p.168, AR2024 p.186), funds-flow tables and cash flow statements (FY21-FY25 results), acquisition notes. Calculations in valuation/calculations.json.

Sources and uses of cash

FY21FY22FY23FY24FY25Total
Adjusted operating profit148.7191.2237.0285.0342.71,204.6
Cash from operations before interest and tax145.9180.6257.3279.7370.51,234.0
of which working-capital investment(12.6)(25.5)(4.2)(8.5)(4.6)(55.4)
Interest paid (incl. fees)(5.6)(15.0)(26.7)(23.2)(26.3)(96.8)
Tax paid(24.2)(40.6)(41.4)(58.4)(76.6)(241.2)
Net capex (capex less disposals)(1.4)(5.5)(21.6)(14.0)(13.1)(55.6)
Leases, employee-trust shares, other(5.9)0.9(3.8)13.8(7.3)(2.3)
Free cash flow (issuer APM)108.8120.4163.8197.9247.2838.1
Acquisitions net of disposals (all-in)(450.5)(177.8)(255.3)(311.0)(29.6)(1,224.2)
Dividends(53.2)(56.4)(70.8)(77.2)(80.9)(338.5)
Equity issued0.6—231.9——232.5
Other(1.2)0.00.04.70.03.5
Change in net debt before FX(395.5)(113.8)69.6(185.6)136.7(488.6)

The "leases, employee-trust shares, other" row is the residual between issuer free cash flow and the lines above it (leases, trust purchases, acquisition fees paid inside operating cash, which the issuer reclassifies to acquisitions, and timing), so it is a reconciling line, not an observed item. FY20 opened with 206.8 of net cash (after a 189.8 equity raise for WCW); FY25 closed with 299.4 of net debt, a change of 506.2, of which 488.6 is cash and 17.6 currency and non-cash.

What the table shows about priorities. Over five years Diploma spent 1,224 on deals, 146% of its free cash flow, and paid 338.5 in dividends (40% of free cash flow). It funded the gap with 232.5 of new equity (plus 189.8 raised just before the window for WCW) and about 506 of net borrowing. Capex was about 1% of revenue, below depreciation in most years. There were no buybacks; employee awards are bought in the market by the trust (about 2-4 a year). Deal spend is lumpy: 450.5 in FY21 (WCW), 311.0 in FY24 (Peerless), 29.6 net in FY25, about 254 in the first three quarters of FY26.

Investment rates per sales change

Window FY21-FY25: revenue rose from 538.4 (FY20) to 1,524.5, a change of 986.1 (salesChangeWindow). Capex, disposal proceeds, D&A and working capital come from each year's own cash flow statement and segment or covenant note (facts ppePurchases*, intangiblePurchases*, ppeDisposalProceeds*, daTangible*, workingCapitalOutflow*). These are audit steps in valuation/calculations.json, not bound to the model.

Rate per £1 of revenue changeFY21FY22FY23FY24FY25FY21-FY25
Revenue change249.0225.4187.5163.1161.1986.1
Incremental M&A (acquisitions net of disposals)1.810.791.361.910.181.24
Internally generated intangiblesn/dn/dn/dn/dn/dnot disclosed
Fixed capital ((net capex − D&A))(3.3%)(2.5%)4.2%(1.2%)(1.2%)(1.0%)
Working capital5.1%12.7%2.2%5.2%2.9%5.9%
Total1.29

Definitions and limits:

  • M&A: all-in acquisition spend net of disposals (1,224.2), including fees, deferred consideration and minorities. The working capital and fixed assets that came with acquired businesses are inside this rate, not in the other two.
  • Intangibles: Diploma capitalises no development spending, and its expensed growth investment (sales capability, engineering, the "upweighting investment in capability" planned for FY26) is not reported separately. Software purchases (5.7 over five years) are already in capex. So no separate rate is shown; FY26 capability spend is expensed growth investment inside the operating margin.
  • Fixed capital: net capex 55.6 (reconciles to the sources-and-uses table) less D&A of PP&E and software 65.6 gives (10.0). Before 23.2 of property disposal proceeds it is +13.2, or 1.3% (fixedCapitalRateGrossWindow). Leases are excluded: right-of-use depreciation (15.5 in FY25) roughly equals lease principal paid (14.6).
  • Working capital: the cash-flow-statement increase, 58.6, which excludes working capital bought with businesses and currency translation. The sources-and-uses table shows 55.4 because the FY23 funds-flow presentation restated FY22 from 28.7 to 25.5; the statutory statement keeps 28.7.
  • The window starts at the Covid trough, so FY21's revenue change includes recovery as well as WCW.

Where Diploma really invests: about 96% of growth investment (1,224 of 1,273) went into acquisitions. Organic growth needed almost no capital. Fixed and working capital of 48.6 against an estimated organic revenue gain of 342.8 is 14p per £1 of organic revenue (organicCapitalRate, an upper bound because part of it served acquired businesses). Acquisitions cost 1.90 per £1 of non-organic revenue (dealCapitalPerAcquiredSales; currency and disposals blur the denominator). So a pound of acquired revenue costs about thirteen times as much capital as a pound of organic revenue. Cross-check: 1/1.90 of revenue per pound at a 22-25% margin is a 12-13% pre-tax return, matching the measured 12.8% deal yield below. Working capital per £1 of organic revenue, about 17% (58.6 / 342.8), is in line with the 15.6-21.5% working-capital-to-revenue stock, which supports the split.

Fixed capital is not a lasting source of cash. Capex below depreciation in four of five years reflects a capital-light distributor, plus property sales (9.9 in FY22) and acquired assets arriving through M&A. Diploma itself expects capex of about 2% of revenue ("usually accounting for around 2% of revenue", FY24 prelim; FY25 capex "at c.1% of revenue was below the 2% we typically expect", FY25 prelim p.10), against D&A of about 1%. At that level the forward fixed rate turns slightly positive, so the negative historical rate should not be extrapolated.

Inflection points and who was in charge (Johnny Thomson CEO throughout; CFO Barbara Gibbes to 30 September 2022, Chris Davies from 1 November 2022 to August 2025, Wilson Ng from August 2025):

  • FY21, M&A 1.81 (Gibbes). WCW, funded by the September 2020 placing and a new term loan.
  • FY22, working capital 12.7% (Gibbes). A deliberate inventory build "to support customer service" during supply-chain shortages; working capital to revenue still improved slightly, to 15.6%.
  • FY23, working capital released to 2.2% and fixed capital turned positive at 4.2% (Davies's first year). Inventory fell 10.8 as supply eased, while capex rose to scale Shoal, Hercules Aftermarket and R&G. M&A was 1.36 (DICSA, T.I.E.), funded by the March 2023 placing.
  • FY24, M&A 1.91 (Davies). Peerless, debt-funded.
  • FY25, M&A 0.18 (Davies, then Ng). A deliberate pause ("walked away from a lot of deals") with 46.6 of disposals; ROATCE rose to 20.9%. Deal spend resumed at about 310 in the twelve months to June 2026, including CDM at about 10x.

No peer rates were computed; peers' filings were not read for this stage.

Reinvestment and returns

Owner earning power, measured as unlevered after-tax adjusted operating profit (25% tax, a matched definition for acquisitions that were funded by a mix of debt and equity):

FY20FY21FY25FY26E (normalised)
Adjusted operating profit87.1148.7342.7444.7
NOPAT at 25%65.3111.5257.0333.5
  • Reinvestment rate FY21-FY25. Growth investment = acquisitions 1,224.2 + working capital 55.4 + net capex 55.6 = 1,335.2. Matching NOPAT = 903.5. Period-weighted reinvestment = 148%: Diploma reinvested more than it earned, funding the excess with equity and debt.
  • Incremental return, lagged. NOPAT change FY20→FY25 = 191.7, against capital deployed FY20-FY24 (deals 1,209.5 incl. FY20's 14.9, working capital and net capex about 90) ≈ 1,300: about 14.7% after tax. This blends organic growth (which needed little capital), margin expansion, the Peerless windfall and acquisitions.
  • Identity check. NOPAT grew 31.5% a year FY20-FY25, while reinvestment (148%) × incremental return (14.7%) is about 22%. The identity does not hold because the window starts at the Covid trough (FY20 margin 16.2% against 17.8% in FY19), ends with the Peerless windfall (about 17 of FY25 profit), and organic growth on the base earned profit with very little capital. Splitting the uses, the identity reconciles:
    • Organic. Base revenue grew 1.637x organically. At the FY20 margin that is 41.6 of extra NOPAT (87.1 × 0.637 × 0.75); if all margin expansion belongs to the base it is 83.3. Working capital and net capex over the window were about 111 (part of it for acquired businesses), so the organic return on new capital was roughly 37-75%. The forward model uses 0.8 (base), from the current working-capital intensity (21.5% of revenue) and a 24% normalised margin.
    • Acquisitions. Measured separately below: 10.6-15.1% pre-tax, 12.8% midpoint, 9.6% after tax.
    • Payouts. Dividends took 40% of free cash flow and grow 5% a year by policy; there were no buybacks.

Diploma's capital-light organic growth is the high-return use; acquisitions earn about their cost of capital on a matched basis (Diploma's own post-tax discount rates are 9.3-9.8%, FY25 note 10), and are worth doing mainly because the acquired niches keep growing on little capital afterwards and because the market capitalises their profit at far more than 10x.

Acquisition record

YearDeal(s)All-in pricePro forma revenuePro forma profit at entryEntry EBIT multipleLater evidence
FY21Windy City Wire (US cable, Oct 2020)347.7175.641.58.4xabout 17% a year organic growth since; margin "strong"
FY21S&W (Denmark medtech)34.9 incl. deferred28.47.64.6xNordics lost a key supplier in FY25
FY21Eight others incl. Techsil, FITT, AHW85.9 incl. deferred60.110.58.2x—
FY22R&G (UK fluid power)99.168.69.710.2xweak UK markets since 2023
FY22Accuscience (Ireland) and five others84.1c.60c.9.1c.9x—
FY23DICSA (Spain)159.779.519.28.3xnew leadership FY25, H2 FY25 growth
FY23T.I.E. (US automation repair)75.128.36.910.9xthe failure case: automation downturn, leadership replaced
FY23Ten others31.0n/dn/dn/d—
FY24Peerless (US aerospace fasteners)243.3129.9 (USD107.7m before purchase)59.9 FY24; underwritten at c.7x FY24 EBIT (c.34)c.7x underwritten (4.1x on FY24 pro forma)profit about 96 in FY25 and about 133 in FY26E (estimates)
FY24PAR and five others50.0c.25c.8.5c.6x—
FY25Alpha Labs, Haagensen, Electramed, Astro, Viking56.146.68.86.4x—
H1 FY26Six deals incl. Swift, WDS, HSA84.659.6 (annualised)14.2 (annualised)6.0x—
Q3 FY26CDM (USD170m, c.USD80m revenue) and three othersc.169 (derived)n/dc.17 (derived from the issuer's c.40 for 15 deals)c.10x—

Aggregate FY21-FY25: about 1,267 of all-in price bought about 156 of entry profit (counting Peerless at its c.34 underwriting, not its windfall-inflated 59.9 pro forma): about 12.3% pre-tax, or 8.1x EBIT. Disposals recycled 46.6 in FY25 at about 6x (nine disposals in five years).

Achieved multi-year deal yield, matched definitions (dealYieldLow/Mid/High):

  • Numerator: FY25 adjusted operating profit (342.7) less what the FY20 base would earn after compounding organic growth (1.637x), less the Peerless profit above a 40% margin (17.0). Low bound: base business at the FY25 group margin (198.1), so acquired profit 127.6. High bound: base business at its FY20 margin (142.6), so acquired profit 183.1.
  • Denominator: all-in deal spend FY21-FY24 plus half of FY25 = 1,209.4, however funded.
  • Result: 10.6% (low), 15.1% (high), 12.8% midpoint pre-tax; 9.6% after tax, a 10.4x purchase multiple of after-tax cash. The upside uses the high bound (8.8x); the downside uses a 9.5x EBIT entry with no growth after purchase (12.7x).
  • Limits: currency effects are not separated (FY24-FY25 translation cut revenue 5% in total); the issuer's organic measure includes acquired businesses' growth after their first year, which moves some deal growth into the base and understates the yield; edge-year timing is approximated by half-weighting FY25.

Correction (2026-11-03, after the open-book calibration). The trap listed in stage 6 was named but not quantified: Peerless entered the issuer's organic measure in FY25 and its revenue gain over the FY24 pro forma (about 66.5, an estimate from the AR2025 sector mix) is about 4.9 of the FY25 11 points. Removing it from the FY20 base's organic factor (organicFactorExPeerless, 1.565 instead of 1.637) moves about 7.5 of FY25 profit from the base to acquisitions: the achieved yield becomes 11.3-15.7% (13.5% midpoint, 10.1% after tax, a 9.9x purchase multiple; dealYieldMidAdj). WCW's growth after its first year is still inside the base (no unit data), so this remains a lower bound. Cross-check: the last 15 deals' entry yield is 12.9% (ltmEntryYield); 12.9% grown about 4% for the 1.1 spend-weighted years a five-year exit captures is about 13.5%.

Achieved (12.8%) is close to entry (12.3%), so in aggregate acquired businesses have earned roughly what was paid for: WCW and DICSA grew, T.I.E., R&G and the Nordics lagged, and Peerless's extra profit is a windfall removed from the numerator.

Observed deployment pace: 244.8 a year net of disposals, 250.1 with FY25 gross of disposals (56.1 invested; the model has no disposal proceeds). The record is lumpy: best year FY21 1.8x the average (WCW, equity-funded), worst FY25 0.22x, longest quiet run one year (FY25; FY20 before it) (dealPaceGross, dealBestYearRatio, dealWorstYearRatio, quietRunYears); the twelve months to June 2026 ran at about 310 (15 deals). About a third of FY20-FY25 deal money came from equity raises, which the forecast does not repeat.

Thesis and valuation

Current assessment:5November2026, after source reconciliation of the revenue-to-owner-cash bridge.

Specialist inventory, technical service and approvals help manufacturers reach fragmented customers. Peerless benefits from aerospace fastener demand and scarcity, but temporary pricing cannot be treated as permanent owner earnings. The current yearly margin path already removes part of that windfall while service and inventory investment continue.

Current valuation

Saved quote GBP 70.45, market time 2026-11-04T17:15:00.000Z; fixed valuation date 5 November 2026 and original model exits. These are forward estimates.

HorizonBearBaseBullWeighted cash-flow IRR
5 years-5.57%7.06%14.92%6.85%
10 years1.33%9.48%14.51%9.57%

The H1 acquisition note supplies £12.5m missing sales and £2.5m missing operating profit directly. The prior £2.82m calendar approximation is retained only as an audit reference; live after-tax missing cash is now £1.875m. Q3 sales are estimated from CDM’s announced USD80m annual revenue, the fixed vintage FX, an explicit 18% CDM operating margin and 21% for residual deals within the existing £17m aggregate Q3 profit estimate. Only missing ownership months enter; estimated integration cash retains its ramp.

Pre-mortem

FY26 starting sales/profit remain guidance-based estimates until 17 November, not reported annual results. CDM and other Q3 deal margins are judgments and are tested over a range, not issuer disclosures. Minority detail, sustaining inventory, Peerless normalization and principal/supplier relationships remain uncertain. No new perpetual scarcity rent or acquisition synergy is added. The central estimate can fail even when a useful product or good acquisition history survives. Customer demand, supplier pricing, the capital needed for delivery and ownership/financing claims must all work together. The adverse case is a representative failure mechanism, not the largest possible loss. No new report or positive share-price move alone resolves these risks.

Exit multiple

The existing 22× base terminal owner-cash capitalization is retained as a conditional judgment after the independent debate. It needs durable profitable reinvestment after exit; tangible operating returns are not the same as goodwill-inclusive acquisition returns. Neither an unreconciled peer P/E nor the 18% CDM margin estimate establishes the terminal multiple. The revenue bridge does not supply independent proof of terminal value or remove the survival risks identified in the written debate. Shorter duration, poorer cash conversion and higher required returns remain relevant stresses. Historical source reproduction and current underwriting remain distinct.

Bear case

FY26 starting sales/profit remain guidance-based estimates until 17 November, not reported annual results. CDM and other Q3 deal margins are judgments and are tested over a range, not issuer disclosures. Minority detail, sustaining inventory, Peerless normalization and principal/supplier relationships remain uncertain. No new perpetual scarcity rent or acquisition synergy is added. The existing adverse operating and capital-allocation paths remain the coherent modeled stress. Matching sales to cash prevents a missing denominator from hiding those assumptions; it does not turn a proxy margin or assumed refinancing into a reported fact. Debt, deferred claims, operating liquidity and distributions remain funded in the same cash ledger.

Variant view

The market treats FY26's 26.5% margin and roughly 40% EPS growth as evidence that Diploma has become a structurally better compounder, and prices it at about 29x FY26E earnings. This research finds that about a quarter of FY26 profit comes from one business, Peerless, whose margin rose from about 30% to about 54% during an aerospace fastener shortage (stage 2, stage 3 independent checks), and that acquisitions have earned about 10% after tax on a matched basis, close to Diploma's own cost of capital (stage 6). The real engine (organic growth on very little capital) is excellent but grows at about 5% a year, which does not justify 31x normalised owner cash. The stock is a high-quality business priced for windfall earnings to persist.

Catalyst: none needed for the view, but the FY26 results and first FY27 guidance on 17 November 2026 are the first test; management has already said FY27 reverts towards its 5% organic model and that margins will moderate.

The source bridge correction changes the central estimate by only a small amount at the same price/date. It does not establish a new market mispricing or justify an unsupported advocate sensitivity. The independent claim judgment still sets the evidence burden; the current numerical returns are the table above.

Why the opportunity exists

The following observations retain the measurement dates in their cited sources; no new holder, liquidity or short-interest survey is claimed.

This is not a neglected stock. Market capitalisation is about £9.7bn (134.3m shares at 7,265p). Three-month average volume is about 651k shares (£47m a day). Excluding the 5%+ notified holders (Capital Group 12.96%, an LLC holder 5.27%, BlackRock 5.02%), the float of about 103m shares would turn over in about 158 trading days. It is a FTSE 100 member, with at least seven sell-side analysts on the Q3 call (Morgan Stanley, Deutsche Numis, BofA, BNP Paribas, Stifel, Kepler Cheuvreux, Berenberg) and an issuer-cited consensus. Short interest and retail ownership were not checked. The shares rose from a 4,970p low to 7,980p in October 2026 on repeated guidance upgrades (March, May, July), then fell about 9% in late October.

So any mispricing is not neglect. It is extrapolation: four upgrades in a year driven by a shortage, priced as a permanent step. The opposite discount (a value opportunity) does not exist at this price; the honest conclusion is that the shares look fully valued to expensive, with a weighted five-year return of about 5%.

What would prove us wrong

FY2026 results on 17 November: replace guidance-based annual sales, disclosed acquisition contributions, Peerless margin/volume and cash conversion, net debt and deferred/minority claims. Compare future observations with the same ownership, cost and reporting periods used in this model. Preserve earlier frozen checks and score them as their reports arrive; do not edit their forecasts to match the result. Unavailable deal disclosure needs a bounded estimate and a revision trigger, not a claim of observed target profitability.

Source bridge and same-price/date changes. The earlier initial completion audit’s three revenue gaps are now closed with reported observations and explicit estimates; the remaining limits above are ordinary underwriting uncertainty, not missing forecast outputs.

Risks & disconfirming evidence

Paths to permanent loss

  1. Paying for a windfall. About 27% of FY26E profit comes from Peerless at a margin (about 54%) well above its pre-acquisition level (c.30%). If aerospace fastener supply normalises and manufacturers or primes take back the economics, group profit falls about 12% with no change elsewhere, and the multiple applied to the rest may fall too. The base deducts 34 of pre-tax profit; the downside about 73.
  2. Multiple compression. At 31x normalised owner cash, the price needs the company's recent high multiples to persist. A move to 22x (still above its historical lows) erases most of five years of earnings growth; 16x produces a loss (bear case -5.9% a year).
  3. Disintermediation. Distributors earn their margin because manufacturers and principals do not want small customers. Peerless's suppliers in a long market, or a Life Sciences principal opening its own subsidiary (the Nordics lost a key supplier in FY25), can remove a business's economics quickly. Diploma's own risk register names this.
  4. Acquisition discipline at a larger scale. The achieved deal yield (about 10% after tax) is close to Diploma's cost of capital. Larger deals (CDM at about 2.1x revenue) and PE competition could push returns below it; an equity-funded deal at a high price would dilute holders, as the FY20 and FY23 raises did (+19% shares since FY19).
  5. End-market cycles. Aerospace build-rate disruption, a US construction downturn (WCW), and UK/Australian industrial weakness (Seals) can coincide. FY20 showed operating profit falling about 10% in a severe shock, which is resilient but not immune.

Unverified inputs (largest first)

InputStatusHow it gets verified
Peerless FY25/FY26 revenue and marginestimated from sector data (46-49% FY25, 53-61% H1 FY26)management commentary; any disclosure of Peerless revenue; Controls margin trend
FY26 operating profit (479.0) and September net debt (348.0)estimated from guidance and H2 cash conversion17 November 2026 results
Q3 FY26 deals' cost (169.3) and profit (about 17)derived from issuer totals; CDM's profit undisclosedFY26 acquisition note
Organic return on new capital (0.7)judgment between measured history and current ratiosworking-capital intensity and FCF conversion in FY27
Exit multiplesjudgment from history, peers and Kollernot verifiable; the main return driver
Acquisition liabilities (39.0)estimated from FY25 balance plus H1 movementsFY26 balance sheet

Disconfirming evidence to watch

  • Controls margin holding above 32% while Peerless grows about 10% a year (the windfall is structural).
  • Ex-Peerless organic growth sustained at 8%+ (upside path).
  • Rising working-capital intensity (inventory above 25% of revenue) without matching growth (the downside's 0.5 organic return).
  • Deal entry multiples drifting above 10x EBIT or acquired businesses shrinking after purchase (downside deal price).
  • New senior-finance changes, control discrepancies, restatements or changes to adjusted-profit definitions. The current management record distinguishes the issuer's explanation of the 2025 departure from independent assurance.

No fieldwork was done, so supplier, customer and employee views are unknown; those are the evidence gaps that would most change confidence in risk 3.

Surviving debate attacks — 5 November 2026

Low to moderate; valuable approvals/inventory service, unresolved Peerless normalization, current earning estimates and cohort sales. Reconstructed the independent isolated stress at the same quote/date/horizons; do not treat stress size as a probability or a measured current fact. Reconstructed the independent isolated stress at the same quote/date/horizons; do not treat stress size as a probability or a measured current fact. Reconstructed the independent isolated stress at the same quote/date/horizons; do not treat stress size as a probability or a measured current fact.

Discriminating evidence: 17 November FY2026: Peerless margin/organic growth, cash conversion, debt and acquisition proforma revenue/profit. The complete debate sizes these risks using the shared forecast; a sensitivity is neither a measured fact nor a calibrated probability.

Revenue bridge closure and remaining uncertainty — 5 November 2026

The previously missing sales/cash perimeter is now modeled. FY26 starting sales/profit remain guidance-based estimates until 17 November, not reported annual results. CDM and other Q3 deal margins are judgments and are tested over a range, not issuer disclosures. Minority detail, sustaining inventory, Peerless normalization and principal/supplier relationships remain uncertain. No new perpetual scarcity rent or acquisition synergy is added. FY2026 results on 17 November: replace guidance-based annual sales, disclosed acquisition contributions, Peerless margin/volume and cash conversion, net debt and deferred/minority claims. This closes the missing forecast output rather than claiming that the target economics or refinancing outcomes are certain. Earlier source-gap statements in the dated debate describe its initial information set; current inputs are in 07-assumption-register.md.

Current assumption register

Assessment:5November2026. Reported facts, issuer pro-forma estimates, normalization and forward judgments remain separately classified.

Reported starting bridge

The H1 acquisition note supplies £12.5m missing sales and £2.5m missing operating profit directly. The prior £2.82m calendar approximation is retained only as an audit reference; live after-tax missing cash is now £1.875m. Q3 sales are estimated from CDM’s announced USD80m annual revenue, the fixed vintage FX, an explicit 18% CDM operating margin and 21% for residual deals within the existing £17m aggregate Q3 profit estimate. Only missing ownership months enter; estimated integration cash retains its ramp.

InputValueClassificationDefinition/evidence
equityCashEarnings341.393underwriting estimateFY26E after-financing owner cash before any Peerless normalisation: (FY26E adjusted operating profit 479.0 - run-rate interest 23.0) x 75% - minorities 0.6 = 341.4, an 18.9% margin on FY26E revenue. Since the revenue build (2026-11-03) the Peerless spot-price windfall fades through the yearly margin path (FY27 47%, FY28 40%) instead of a deduction from the base; the normalised 319.9 remains as a cross-check of the FY28 margin. Sources: dplm-fy25-prelim, dplm-h126, dplm-q326, dplm-ar25, dplm-peerless-rns, yahoo-fx
shares134.317reported denominator134.317m ordinary shares in issue (AR2025 p.98); the employee trust's 81k shares are ignored. Sources: dplm-ar25
openingCash0.000underwriting policyZero investable cash. Diploma runs on its revolving facility; reported cash (68.7 in March) is operating cash inside net debt, which is carried as a claim. Sources: dplm-h126
revenue1807.675derived estimateFY26E revenue 1,807.7 = FY26E adjusted operating profit / the guided 26.5% FY26 margin (July 2026 update, nine months reported). Replace with the reported FY26 figure on 17 November 2026. Sources: dplm-q326, dplm-fy25-prelim

Known and committed cohort bridge

Revenue is consolidated gross; cash is on the model’s common-owner or cash-NOPAT perimeter. A reported sales observation is not a reported cash margin. Missing months exclude sales already in the starting baseline. Capital already paid or reserved is not purchased again.

CohortMissing annual salesMissing/mature cashTiming and basis
H1 FY26 bolt-ons, missing months12.5001.875Issuer H1 note 10 reports 12.5m missing sales and £2.5m operating profit directly. Pro-forma numbers extrapolate actual post-close performance; these are estimates of missing ownership months, not newly reported full-year sales. After-tax profit is an owner-cash proxy with depreciation charged; no integration uplift. Add only the periods not already in FY26E. Sources: dplm-h126
Q3 FY26 deals incl. CDM, missing months67.0969.563Estimated from the issuer's c.40 annualised profit on c.310 for the 15 LTM deals; CDM's own profit is undisclosed, so it ramps over a year. Missing revenue is estimated independently from CDM80m USD announced annual sales at fixed FX, explicit 18% CDM operating margin and 21% for the residual four deals, bounded by the existing issuer aggregate profit. Only75% absent ownership months enter; sales and cash retain the one-year ramp. The margin assumptions are not reported target margins. Sources: dplm-h126, dplm-q326, dplm-q326-transcript

Forward scenario mechanisms

Specialist inventory, technical service and approvals help manufacturers reach fragmented customers. Peerless benefits from aerospace fastener demand and scarcity, but temporary pricing cannot be treated as permanent owner earnings. The current yearly margin path already removes part of that windfall while service and inventory investment continue.

The existing 22× base terminal owner-cash capitalization is retained as a conditional judgment after the independent debate. It needs durable profitable reinvestment after exit; tangible operating returns are not the same as goodwill-inclusive acquisition returns. Neither an unreconciled peer P/E nor the 18% CDM margin estimate establishes the terminal multiple.

downside

Aerospace fastener supply catches up: Peerless revenue falls about 20% over FY27-FY28 and its margin returns to about 30% (owner-cash margin 17.3% in FY27, 16.3% after); UK and European industrial markets stay weak, so organic revenue is flat for two years, then grows 2.5%. Deals stop to FY25's 56 for two years (a dry spell longer than the record's), then return to 250, at 9.5x EBIT (2.0x revenue), growing 2.5% after purchase. Exit at 16x, near Diploma's trough trailing multiples (18-21x) less a further step for a slower business.

DriverValue/pathReason and sources
roiic0.500Owner cash per unit of new working capital and capex: 0.5. About 13% after-tax margin on new revenue against 25% working capital (as in H1 FY26, when inventory rose 44.1 to secure supply); near the low end of the FY20-FY25 measured 37-75%.
exitMultiple16.00016x after-financing owner cash. Diploma's lowest trailing adjusted P/E in FY2017-FY2025 was 18-21x (FY20 trough about 18x). A slower business with 3% growth and no deal runway justifies about 16-17x at a 9% required return (Koller value driver).
dilutionRate0.000No new shares: share-based pay (6.2 in FY25) stays charged in owner cash and awards are bought in the market by the employee trust. Weighted shares rose about 0.1% a year in FY24-H1 FY26.
reinvestmentRate1.000All cash after dividends and organic investment is offered to acquisitions, but annual purchases are capped at the observed pace. No new borrowing in the model, although the board allows leverage up to 2x.
organicGrowth, years 1–20.000Bear: aerospace fastener supply catches up and Peerless revenue falls about 20% over two years, while UK and Australian Seals stay weak; 2-3% growth elsewhere is offset, so group organic revenue is flat in FY27-FY28. Sources: dplm-q326-transcript, dplm-h126, dplm-fy25-prelim
organicGrowth, years 3–100.025From FY29 2.5%: replacement and consumable demand (about 45% of profit) plus a weaker capex cycle; near FY24's 6% organic year less pricing and the Covid-year pattern. Sources: dplm-q326-transcript, dplm-h126, dplm-fy25-prelim
organicMargin, years 1–10.173FY27 17.3%: Peerless margin falls to 40% on revenue down 10%; rest of the group held at 22.2% (it kept 19-24% sector margins through FY20). Same interest, tax and minority shares as the base. Sources: dplm-q326-transcript, dplm-h126, dplm-fy25-prelim, dplm-peerless-rns
organicMargin, years 2–100.163From FY28 16.3%: Peerless at about 30%, its pre-acquisition margin, on revenue 20% lower; operating margin 23.0%. A cyclical reversal, not a permanent group margin collapse. Sources: dplm-q326-transcript, dplm-h126, dplm-fy25-prelim, dplm-peerless-rns
priceToSales, years 1–101.9952.0x revenue (priceToSalesDownside): 9.5x EBIT at a 21% margin, the price larger, defence-exposed assets like CDM (about 10-11x) command. Sources: dplm-q326-transcript, dplm-h126, dplm-fy25-prelim, dplm-q326-transcript
acquiredMargin, years 1–100.15815.75% owner-cash margin, as in the base: entry margins don't change with the scenario; the downside prices them dearer. Sources: dplm-q326-transcript, dplm-h126, dplm-fy25-prelim
acquiredGrowth, years 1–100.0252.5%: the downside rate of the non-Peerless portfolio, under the issuer's organic definition; T.I.E.-type laggards weigh on cohorts. Sources: dplm-q326-transcript, dplm-h126, dplm-fy25-prelim
deploymentCapacity, years 1–256.000FY27-FY28: a two-year dry spell at FY25's 56, one year longer than the record's longest quiet run (FY25; FY20 before it). An aerospace and industrial downturn plus higher prices for larger assets (CDM about 10-11x) make Diploma walk away, as it did in FY25. Sources: dplm-ar25, dplm-fy25-prelim, dplm-h126, dplm-q326-transcript
deploymentCapacity, years 3–10250.000FY29-FY36: back to the through-cycle average of 250, not grown: a slower business with a smaller deal runway. Sources: dplm-ar25, dplm-fy25-prelim, dplm-h126, dplm-q326-transcript

base

Revenue build from FY26E revenue (1,807.7) at an 18.9% owner-cash margin. Organic revenue grows 5% in FY27 (management's guide back towards its model), then 5.65% (sector rates weighted by revenue). Peerless's spot-price margin fades from 54% to 47% in FY27 and 40% in FY28 on 9% volume growth, taking the owner-cash margin to 17.6%; mix then lifts it towards 18.0%. Deal budget 250 a year in FY27-FY28 (the FY21-FY25 average), 280 in FY29-FY31 and 320 after; bought at 1.63x revenue (a 21% operating margin at the last 15 deals' 12.9% entry yield) and growing at the non-Peerless rate (4.4%, then 5.1%); about half a year's profit arrives in the purchase year; retained cash saves facility interest; new capital at an 0.6 owner-cash return. Exit at 22x after-financing owner cash.

DriverValue/pathReason and sources
exitMultiple22.00022x after-financing owner cash. Own history: trailing adjusted P/E averaged 25-32x in FY2017-FY2025 (excluding FY21's Covid distortion), with lows of 18-24x. Koller value driver at the exit: 5% growth, half organic at 0.8 and half acquired at about 9.7%, implies reinvesting about 29% of earnings; (1-0.29)/(8.5%-5%) = 20-21x, or 24x at 8%. 22x is below the average history because the history includes years when the market priced Peerless-type windfalls and faster deal growth.
dilutionRate0.000No new shares; share-based pay stays charged. No repeat of the FY20/FY23 equity raises is modelled.
reinvestmentRate1.000All surplus cash after dividends and organic investment goes to deals, capped at the observed pace. Unplaced cash is retained at face value (in practice it would repay debt).
organicGrowth, years 2–100.056FY28 onwards: sector rates weighted by FY25 revenue, Controls 7% (Peerless near 10% after FY26, defence, WCW's datacentre and building cable), Seals 4% and Life Sciences 4% (opportunity ledger, 08-underwriting-plan) = 5.65% (organicRevenueGrowthBase). Below the FY21-FY25 record of about 10% a year, which included inflation and Peerless's shortage years. Sources: dplm-q326-transcript, dplm-h126, dplm-fy25-prelim
organicMargin, years 1–10.183FY27 owner-cash margin 18.3% (ownerMarginY1): Peerless halfway through its spot-price fade, 54% to 47%, on revenue up 9%; the rest of the group at its FY26E 22.2% operating margin; interest held at 1.27% of revenue; 25% tax. Sources: dplm-q326-transcript, dplm-h126, dplm-fy25-prelim, dplm-peerless-rns
organicMargin, years 7–100.180FY33-FY36 18.0%: the same mix drift continues (Peerless about 18% of revenue by FY36 against 14% today), operating margin about 25.2-25.5%; the average of yearly values of 17.9-18.1%. Still below FY26E's 18.9% owner-cash margin, which contains the spot-price windfall. Sources: dplm-q326-transcript, dplm-h126, dplm-fy25-prelim
acquiredGrowth, years 1–10.044FY27 4.4% (restGrowthY1): the issuer counts acquired businesses as organic after their first year, and they resemble the non-Peerless portfolio, so they grow at its FY27 rate. Sources: dplm-q326-transcript, dplm-h126, dplm-fy25-prelim
deploymentCapacity, years 1–2250.140FY27-FY28: the through-cycle average of 250 a year (FY21-FY25, FY25 gross; dealPaceGross). Known deals are already in their year: CDM and the other Q3 FY26 deals (about 169) and the H1 FY26 deals (84.6) closed in FY26 and sit in the baseline and funded cohorts, not in this budget. No completed or financed FY27 deal is disclosed before the 17 November results. The LTM pace (about 310) is a recent high and is not extrapolated. Sources: dplm-ar25, dplm-fy25-prelim, dplm-h126, dplm-q326-transcript
deploymentCapacity, years 3–5280.000FY29-FY31: 280 a year. The average scaled with the group: owner cash grows about 5-6% a year, and the pipeline (about 50 live opportunities, typical deal 20-25m) and M&A staff grow with it. A level budget averages the lumpy years; it doesn't predict which year is quiet. Sources: dplm-ar25, dplm-fy25-prelim, dplm-h126, dplm-q326-transcript

upside

Structural end markets (aerospace build backlog, defence, datacentres, energy) keep organic revenue growth at 7.5%, near the seven-year record; Peerless eases only to 47-50%, so the owner-cash margin stays about 18.4-18.7%.

DriverValue/pathReason and sources
roiic0.9000.9: incremental margins of 29-36% (FY24, FY25) on new revenue against about 22% working capital and capex, near the top of the measured range.
exitMultiple27.00027x, below the FY24-FY25 averages (31-33x trailing). Koller at 6% growth, 8.5-9% required return and a higher organic share gives 26-31x.
dilutionRate0.000No new shares.
reinvestmentRate1.000All surplus offered to deals, capped.
organicGrowth, years 1–100.0757.5% a year: near the seven-year organic record (7%) plus share gains in structural end markets (aerospace build backlog, defence, datacentres); H1 FY26 ex-Peerless growth was high single digit. Peerless about 10%, the rest about 7.1%. Sources: dplm-q326-transcript, dplm-h126, dplm-fy25-prelim
organicMargin, years 1–10.185FY27 18.5%: Peerless eases only to 50% as volume holds. Sources: dplm-q326-transcript, dplm-h126, dplm-fy25-prelim, dplm-peerless-rns
organicMargin, years 2–50.184FY28-FY31 18.4%: Peerless holds near 47% (management: structurally above the purchase level); the rest at 22.2%; average of yearly mix values 18.3-18.5%. Sources: dplm-q326-transcript, dplm-h126, dplm-fy25-prelim, dplm-peerless-rns
organicMargin, years 6–100.187FY32-FY36 18.7%: Controls and Peerless keep gaining share; average of yearly mix values 18.6-18.8%. Sources: dplm-q326-transcript, dplm-h126, dplm-fy25-prelim
acquiredMargin, years 1–100.15815.75% owner-cash margin, as in the base. Sources: dplm-q326-transcript, dplm-h126, dplm-fy25-prelim
acquiredGrowth, years 1–100.0717.1%: the upside rate of the non-Peerless portfolio (7.5% group less Peerless at 10%). Sources: dplm-q326-transcript, dplm-h126, dplm-fy25-prelim
deploymentCapacity, years 1–2310.000FY27-FY28: the LTM pace (about 310 for 15 deals) holds as the pipeline 'bigger than ever' converts. The engine places only what cash allows, as no borrowing is modelled. Sources: dplm-ar25, dplm-fy25-prelim, dplm-h126, dplm-q326-transcript
deploymentCapacity, years 3–5380.000FY29-FY31: 380 a year, as larger platform deals (about 1.2-1.5x the average, like FY24's 311) recur. Sources: dplm-ar25, dplm-fy25-prelim, dplm-h126, dplm-q326-transcript
deploymentCapacity, years 6–10450.000FY32-FY36: 450 a year, a FY21-sized year on average, matching a group about twice FY21's size. Sources: dplm-ar25, dplm-fy25-prelim, dplm-h126, dplm-q326-transcript

Estimation limits and revision triggers

FY26 starting sales/profit remain guidance-based estimates until 17 November, not reported annual results. CDM and other Q3 deal margins are judgments and are tested over a range, not issuer disclosures. Minority detail, sustaining inventory, Peerless normalization and principal/supplier relationships remain uncertain. No new perpetual scarcity rent or acquisition synergy is added.

FY2026 results on 17 November: replace guidance-based annual sales, disclosed acquisition contributions, Peerless margin/volume and cash conversion, net debt and deferred/minority claims.

Named arithmetic, stable fact IDs and source links are retained in valuation/calculations.json. Inputs were selected before inspecting the revised IRR; the earlier source result and prior models are not overwritten.

12 November share-plan notice

The original RNS body applies to admit 249,058 shares under the 2020 Performance Share Plan, expected 16 November. It is not an exercise, settlement or updated voting-rights notice. pspBlockListingApplication20261112 records the application; the live share count and existing economic compensation treatment stay unchanged. Reconcile actual issue/treasury movements, buybacks and charged compensation in the next accounts before adding dilution or a second replacement-cost charge. The host’s generated summary is not the original RNS.

Underwriting plan

Written with the scenario inputs; returns were run once only to check the engine (see the assumption register for the two corrections made afterwards and their effect).

Opportunity ledger

OpportunityStarting point (FY25 / FY26E)Customer need and why Diploma winsReachable revenue in five yearsInvestment and cash costTiming and limitsEvidence against
Aerospace fasteners volume (Peerless, Clarendon, Swift)Peerless c.196 / c.245; Clarendon c.110Certified, traceable parts delivered to subcontractors on schedule; a "10+ year backlog" of aircraftVolume growth near 10% a year at Peerless after FY26 (management)Inventory: Peerless carried 65.6 of inventory on 130 of revenue at purchase (50%)Build rates depend on Boeing/Airbus ramps; fastener supply is catching upSpot premiums fade as supply improves; manufacturers may sell direct
Aerospace spot price (Peerless margin)about 54% margin FY26E vs c.30% before purchaseShortage pricingNegative: base assumes the margin falls to 40% (already deducted)—FY27 onwardManagement is already "easing off the margin"
European and US defence (IS Group, Clarendon, Spring, CDM)6-7% of group revenue pro forma incl. CDMInterconnect and fasteners for defence primes; new facility in the Czech RepublicDouble-digit growth plausible from a small baseInventory and facilities; CDM cost USD170mDefence budgets rising in Europe; US is new (CDM)Programme delays; defence primes' pricing power
Datacentre and building cable (WCW, Shoal)Datacentres c.15% of WCW, c.3% of groupSpecified cable delivered to site; WCW grew 17% a year since 2020Mid to high single digits through the cycleInventory, copper price pass-throughConstruction cycle; datacentre build-out may slowCustomer concentration in hyperscale builds; national distributors
Seals aftermarket and OEM456 revenue, 2% organic FY25, 2% H1 FY26Repair parts with same-day availability; e-commerce two-thirds of Hercules Aftermarket sales3-5% a year if UK and Australia recoverSmallUK construction and agriculture; tariffsLong UK weakness; R&G underperformance since 2022
Life Sciences232, 4-6% organicLocal market access for device and diagnostic makers3-5% a yearSmall; agency renewalsProduct-lifecycle refresh in FY26Supplier loss (Nordics FY25); principals going direct
Bolt-on acquisitions244.8 a year average; c.310 LTMFounders sell to a decentralised owner; Diploma walks away from many deals1,335 deployed over five years in the base (cash-funded)All-in price at 9.9x after-tax cash (13.5% pre-tax achieved, corrected 2026-11-03 for Peerless growth counted as organic; 10.4x / 12.8% before)Capacity grows 5% a year in the basePE competition; bigger deals at higher multiples (Q3 deals about 10x)

Overlap: acquired businesses' later growth is inside the deal yield, not the organic rate, because the engine holds acquired cohorts flat; only the growth inside the measured FY21-FY25 window is captured (an omitted mechanism, see the 2026-11-03 calibration note). Peerless volume growth is part of the group organic rate; its price windfall is removed once, in the baseline, priced at the revenue Peerless reaches when its margin normalises (FY28).

Base organic rate (revised 2026-11-03): weight the ledger's own sector rates by FY25 sector profit instead of adopting the issuer's 5% model. Controls (65% of sector profit) at 7%, Seals (23%) at 4%, Life Sciences (12%) at 4% gives 5.96% (organicGrowthBase). Evidence against: management expects FY27 to revert towards the 5% model after FY26's 14% and against tough comparisons; a single ten-year rate cannot show that dip (about -0.1 points a year at ten years).

Absolute scale check (base, year 5 ≈ FY31): revenue at the FY26 perimeter is about 1,900 (FY26E about 1,800 plus the Q3 deals' missing months). Growing about 6% organically gives about 2,540 by FY31 (2,425 at the earlier 5%). About 1,335 of deals at about 10x EBIT and a 20% margin add about 670 of revenue. Total revenue is about 3,100, roughly 1.7x FY26E. At a normalised 24% margin that is about 740 of operating profit and about 540 of owner cash after interest and tax, consistent with the model's 514 in year 5 plus the retained cash it holds instead of repaying debt. Diploma had about 3,500 staff in July 2026; at constant revenue per employee it would need about 5,900 by FY31. Management calls this kind of scaling its main focus. The number of deals implied (about 15 a year at FY26 deal sizes) equals the record LTM pace.

Management targets as bounds. The financial model (5% organic, 10% total growth, 20%+ margin, double-digit EPS growth, high-teens ROATCE, <2x leverage) is the issuer's medium-term ambition. The base sits about one point above the organic target (5.96%, from sector weights; the target was the base until 2026-11-03), below the 10% total-growth target (because no new debt or equity is used), and at a lower margin than FY26's 26.5% (because of the Peerless normalisation). The PSP's maximum vesting (13% EPS CAGR from FY25) is above the base.

Scenario mechanisms

DownsideBaseUpside
Peerlessmargin to about 30% and spot volume falls; an extra 39 of pre-tax profit lost beyond the base normalisationmargin normalises to 40% by FY28 while revenue grows about 9% a year (excess of 28.7 deducted in the baseline; 34.4 before 2026-11-03)margin holds nearer 47% (not modelled as a baseline add-back; covered by higher growth)
Organic revenue growth (yearly path)0% FY27-FY28, then 2.5%5% FY27, then 5.65%7.5%
Owner-cash margin (yearly path, from 18.9%)17.3% FY27, 16.3% after (Peerless to 30%)18.3% FY27, 17.6% FY28, 17.75% FY29-32, 18.0% FY33-3618.5% FY27, 18.4% FY28-31, 18.7% FY32-36
Organic return on new capital0.5 (inventory-heavy growth)0.6 (0.7 before the 2026-11-03 claim reconstruction)0.9 (operating leverage)
Deal budget (yearly path)56 in FY27-FY28 (dry spell), then 250250 FY27-FY28, 280 FY29-FY31, 320 FY32-FY36310 FY27-FY28, 380 FY29-FY31, 450 FY32-FY36
Financing and dilutionnonenonenone
Exit (after-financing owner cash)16x22x27x

Mechanisms behind each assumption:

  • Downside. The windfall reverses faster and further than the base (a supply-driven premium, with management already cutting spot prices), and Seals' UK/Australian weakness persists. That is a temporary under-use of a still-good franchise, not a permanent impairment: the group held 16%+ margins through Covid. The lower exit multiple comes from slower growth and a smaller deal runway, not from the lower earnings themselves. Deals continue because the board has kept buying through weak years (FY23-FY24).
  • Base. The rest of the portfolio grows at the profit-weighted sector rate (5.96%); the issuer's own 5% model, beaten in five of the last six years, is now a bound rather than the forecast; deals continue at the measured achieved yield and the observed pace.
  • Upside. Requires the structural end markets to keep ex-Peerless growth near high single digits (as in H1 FY26) and the deal engine to scale. The higher multiple needs its own mechanism: more organic growth at higher incremental returns raises the Koller value-driver multiple (6% growth at 8.5-9% gives 26-31x). It is not granted by growth alone.

Funding: every scenario funds deals and organic investment from owner cash after dividends before any contribution, with a one-year delay; no scenario needs external finance (the engine would reject it). Adapter choice: equity-acquirer, because Diploma's owner cash after interest is the right claim, it pays a fixed progressive dividend, organic investment needs a return-on-capital charge, and deal capacity must be capped. The debt-funded capital-acquirer adapter was rejected because it forces zero organic growth and deploys to a debt ceiling every year without a capacity cap; neither fits Diploma. The cost of the choice: the model cannot borrow up to the board's 2x policy or issue shares, so it understates the deal capacity Diploma has actually used.

Revenue build (3 November 2026)

Owner cash is now revenue x margin on yearly paths, each with a written reason in valuation/model.json (inputs.yearly), computed in calculations.json (fy26Revenue, startingOwnerMargin, ownerMarginY1, ownerMarginY2, organicRevenueGrowthBase, restGrowthY1/Y2, priceToSalesBase). Starting point: FY26E revenue 1,807.7 and owner cash 341.4, an 18.9% margin that still contains the Peerless windfall. The fade is a margin path instead of a deduction. Base revenue reaches about 3,110 organic plus about 2,120 acquired by FY36 (about 5,230 in total, 2.9x FY26E), at a 17.1% blended owner-cash margin, because acquired businesses earn 15.75%.

Revenue bridge closure — 5 November 2026

The H1 acquisition note supplies £12.5m missing sales and £2.5m missing operating profit directly. The prior £2.82m calendar approximation is retained only as an audit reference; live after-tax missing cash is now £1.875m. Q3 sales are estimated from CDM’s announced USD80m annual revenue, the fixed vintage FX, an explicit 18% CDM operating margin and 21% for residual deals within the existing £17m aggregate Q3 profit estimate. Only missing ownership months enter; estimated integration cash retains its ramp.

5-year base revenue 3221.658, operating owner cash 553.600 (GBPm). 10-year base revenue 5234.784, operating owner cash 894.324 (GBPm). The original customer/opportunity and acquisition-budget reasoning remains; this correction does not infer new demand from a matched denominator. FY26 starting sales/profit remain guidance-based estimates until 17 November, not reported annual results. CDM and other Q3 deal margins are judgments and are tested over a range, not issuer disclosures. Minority detail, sustaining inventory, Peerless normalization and principal/supplier relationships remain uncertain. No new perpetual scarcity rent or acquisition synergy is added.

Source arithmetic and old/new inputs.

Capital productivity and reinvestment

Assessment:5November2026. These are shared-engine diagnostics from the same owner-cash projection shown in the dashboard, not a new historical measurement. Money is in GBP millions.

HorizonScenarioReturn/proxy definitionRatePeriod-weighted reinvestmentNew growth capitalMatching earningsFunding residual
5 yearsdownsideAcquisition ROIIC · mature cash proxy7.89%51.68%909.3711759.5682.27e-13
5 yearsbaseAcquisition ROIIC · mature cash proxy9.68%66.06%1504.7502277.9790.00e+0
5 yearsupsideAcquisition ROIIC · mature cash proxy10.00%73.15%1861.6212544.8624.55e-13
10 yearsdownsideAcquisition ROIIC · mature cash proxy7.89%53.36%2265.7564246.1924.55e-13
10 yearsbaseAcquisition ROIIC · mature cash proxy9.68%55.17%3406.1226173.6039.09e-13
10 yearsupsideAcquisition ROIIC · mature cash proxy10.00%59.60%4447.2757462.0980.00e+0

The H1 acquisition note supplies £12.5m missing sales and £2.5m missing operating profit directly. The prior £2.82m calendar approximation is retained only as an audit reference; live after-tax missing cash is now £1.875m. Q3 sales are estimated from CDM’s announced USD80m annual revenue, the fixed vintage FX, an explicit 18% CDM operating margin and 21% for residual deals within the existing £17m aggregate Q3 profit estimate. Only missing ownership months enter; estimated integration cash retains its ramp.

Reinvestment is total new growth investment divided by total matching earnings, not an average of annual percentages. Previously funded cohort contributions are not new investment returns. Acquisition cash-yield proxies and forecast-implied productivity are not measured historical ROIIC or project IRRs. All dividends, existing claims, liquidity and financing are reconciled before new purchase capital.

FY26 starting sales/profit remain guidance-based estimates until 17 November, not reported annual results. CDM and other Q3 deal margins are judgments and are tested over a range, not issuer disclosures. Minority detail, sustaining inventory, Peerless normalization and principal/supplier relationships remain uncertain. No new perpetual scarcity rent or acquisition synergy is added.

Historical measurements and definitions remain in 04-capital-allocation.md and valuation/calculations.json. Dated source bridge and funding ledger.

Scenario probabilities

Assessed 3 November 2026. Coarse, subjective weights on three joint business paths, defined in research/08-underwriting-plan.md before the weights were chosen. They are not fitted to any return, issuer guidance or external forecast; no investor reference was consulted (blind test). Stored in valuation/model.json → scenarioProbabilities.

HorizonDownsideBaseUpside
5 years25%50%25%
10 years25%50%25%

Five years. The window spans the likely Peerless normalisation and at least one industrial cycle. Downside 25%: supply-driven spot premiums usually fade once manufacturers add capacity; Peerless already earns more than 50% against c.30% before purchase, management is already trimming spot prices, and Seals' UK weakness persists. Base 50%: diversified niches, 7% organic growth over seven years and stable 19-24% sector margins support profit-weighted sector growth of about 6% (5% before the 2026-11-03 revision, which had used the issuer's financial model) with deals at the measured yield. Upside 25%: aerospace backlog, defence, datacentres and energy, and high-single-digit ex-Peerless growth in H1 FY26, make sustained 8% growth and faster deal capacity plausible but not central.

Ten years. The deal record and organic franchise matter more than the Peerless cycle, but there are more cycles and a growing risk that deal capacity cannot keep growing at the measured yield as the group gets bigger. There is no evidence-based reason to tilt the weights away from the five-year view, so they are unchanged; this is a judgment, not a default.

Weighted returns at 7,265p (IRR of probability-weighted dated cash flows): 6.2% (5 years), 9.2% (10 years), after the 2026-11-03 calibration revision, engine-policy update, claim reconstruction, revenue build and the 4 November yearly deal budgets (blind version 4.9% and 8.0%). The weights were re-affirmed, not changed: the revision corrected a debt definition, the Peerless normalisation revenue, the base growth rule, the deal-yield measurement and (with new engine policies) acquired-cohort growth, part-year deal profit and a return on retained cash, but each path keeps its mechanisms.

Limits: low confidence; the sources support the mechanisms, not the odds. Three paths approximate a wider distribution; a deep aerospace or industrial recession with a de-rating below 16x, or a large equity-funded deal, lies outside them. The weights are joint path weights, not independent driver probabilities. Price moves alone do not change them; the FY26 results (17 November 2026) and Peerless's FY27 trajectory are the next evidence. A local override of any scenario input suspends these weights until reviewed.

Source bridge review — 5 November 2026

The revenue-to-cash coverage gap is closed. The H1 acquisition note supplies £12.5m missing sales and £2.5m missing operating profit directly. The prior £2.82m calendar approximation is retained only as an audit reference; live after-tax missing cash is now £1.875m. Q3 sales are estimated from CDM’s announced USD80m annual revenue, the fixed vintage FX, an explicit 18% CDM operating margin and 21% for residual deals within the existing £17m aggregate Q3 profit estimate. Only missing ownership months enter; estimated integration cash retains its ramp. Existing horizon-specific weights were reassessed and retained: the core joint demand/capital scenarios have not been replaced and exact numerical frequency evidence has not appeared. FY26 starting sales/profit remain guidance-based estimates until 17 November, not reported annual results. CDM and other Q3 deal margins are judgments and are tested over a range, not issuer disclosures. Minority detail, sustaining inventory, Peerless normalization and principal/supplier relationships remain uncertain. No new perpetual scarcity rent or acquisition synergy is added. These are subjective estimates, not measured odds.

Bull–bear review — Diploma PLC, 5 November 2026

Subsequent source closure: the missing revenue bridge identified in this debate has now been completed. Current source-derived estimates, corrections and same-price/date effects. The original independent argument record below is retained with its information set; it is not a claim that all estimated target margins have become reported facts.

Independent advocates prepared opening cases without seeing the other draft, then exchanged point-by-point cross-examinations. A separate judge who did not author the prior model assessed the competing claims. Source reconstructions retain their stated provenance; inaccessible private reports were not newly read. Quoted sensitivities test arguments and are not automatically adopted forecasts.

Fixed quote GBP 70.45, market time 2026-11-04T17:15:00.000Z; valuation date 2026-11-05. Original forecast exits retained.

HorizonBefore bear/base/bullAfter bear/base/bullWeighted before → after
5 years-5.56% / 7.07% / 14.94%-5.56% / 7.07% / 14.94%6.86% → 6.86%
10 years1.34% / 9.48% / 14.51%1.34% / 9.48% / 14.51%9.57% → 9.57%

Bull case

As of 5 November 2026. No opposing advocate draft was read. Existing company research, fact/calculation ledgers and exact registered source locators were examined; original issuer sources additionally checked live: Lumine Q3, CSU Q2, Diploma Q3 transcript, NVIDIA CFO commentary, TerraVest Highland/KBK, WOSG FY26. Harvia Q3 PDF retrieval failed; its registered extraction remains the evidence limit. Private source interpretations below are the repository's documented reconstruction, not a new claim to have read an unavailable private original.

The strongest bear case is paying a quality multiple for a temporary aerospace fastener shortage, while new acquisitions earn only around the cost of capital. Peerless's undisclosed present margin and revenue make group quality insufficient proof of durable current earning power.

DPLM-B1 — Organic demand may beat the subdued base. The issuer's acquired Peerless had approximately 9% long-term organic growth before the shortage; aerospace production backlogs, defence and datacentre cable provide identifiable demand. Test the existing upside 7.5% yearly organic path, holding base margins and deals. Sources dplm-peerless-rns, pp.1–2; dplm-q326-transcript, pp.1–3; dplm-h126, sector reviews pp.7–11. H1 ex-Peerless growth supports the possibility, but the outside view must exclude inflation and shortage years; datacentres are only~3% of the group.

DPLM-B2 — Some Peerless uplift may survive. Specialist inventory, approvals and service availability are customer value, not merely spot prices. Management says the eventual margin should be structurally above acquisition, below today (dplm-q326-transcript, PDF p.5). Test upside organicMargin only. dplm-peerless-rns, pp.1–2 gives~30% acquisition EBIT margin; the current~54% is reconstructed, not disclosed. Retaining stronger margin belongs in upside until actual disclosure resolves it.

Test27× versus 22× as duration exposure, not an adopted multiple.22× needs about 14 years after exit at 10% growth, 20% blended marginal return and 8.5% required return in a finite-growth diagnostic. The advantage is service/approval density across small niches; principal loss, competition and larger deals can shorten it. A permanent high organic ROIIC cannot be transferred to acquisitions. Lack of funded-cohort sales and FY26 results not due until 17 November prevent high conviction.

Isolated shared-engine effects

Saved quote 70.45; market timestamp 2026-11-04T17:15:00.000Z. Fixed valuation date 2026-11-05; model ff 31833da2d3; exits remain the original model vintage. These are sensitivities, not joint forecasts or probability revisions. Baseline base IRR 7.07% / 9.48% (5/10 years).

ClaimExact input/path5-year base10-year baseChange, pp (5/10)
DPLM-B1cases.base.inputs.yearly.organicGrowth8.58%10.77%+1.51 / +1.29
DPLM-B2cases.base.inputs.yearly.organicMargin7.73%9.79%+0.66 / +0.31
DPLM-B3cases.base.inputs.exitMultiple11.39%11.52%+4.31 / +2.04

Bear case

Strongest opposing case

Diploma's service, approvals and inventory allow manufacturers to reach small customers economically, producing high tangible capital returns. Ex-Peerless organic growth was 10% at the Q3 update, and management describes high-single-digit to 10% longer-run Peerless volume growth, so attributing all FY26 strength to one temporary shortage would be wrong. [dplm-q326-transcript PDF pp.2–4.]

Bear case

The stock still prices a high-quality distributor as though unusually favorable aerospace pricing has become durable earning power. Peerless's estimated 53–61% first-half margin compares with about 30% before purchase. The estimate is reconstructed from Controls disclosure, not a disclosed Peerless P&L, so neither bull nor bear should pretend to know its exact margin. Management explicitly expects growth to moderate, is reducing margins and expects FY27 to return toward the usual financial model. That is stronger evidence than price momentum or the reputation of the acquirer. [dplm-peerless-rns pp.1–2; dplm-ar25 pp.22–23; dplm-h126 sector tables; dplm-q326-transcript pp.2–4.]

The current base already normalizes some of this windfall through an annual margin path. The challenge is whether 17.75–18.03% owner-cash margins and 5.65% organic revenue growth sufficiently allow for lost supplier scarcity and inventory funding. Peerless's purchase inventory was roughly half annual sales. If primes or fastener manufacturers reclaim the spread as supply normalizes, replacement demand protects volume but cannot protect the distributor's price. The Nordics lost a Life Sciences principal: supplier relationships are valuable while suppliers want them, not owned in perpetuity. [dplm-fy24-prelim acquisition note 11; dplm-fy25-prelim Life Sciences review; research/01-business.md representative units.]

The matched deal yield is around 10% after tax, much less than the return on tangible operating capital. Paying for goodwill and funding inventory matters. A22x base exit can be rational only with further profitable growth beyond 2031. The present Koller check uses perpetual 5–6% growth and 8–8.5% required returns; it does not establish a finite duration of the advantage or a matched peer cash denominator. The low current forward return leaves little cushion if the duration shortens. [research/04-capital-allocation.md matched deal arithmetic; dplm-fy21-prelim through dplm-fy25-prelim acquisition notes; research/05-thesis.md Exit multiple.]

Contested claims

  • DPLM-B1 —Test16x exit against 22x base; 16x is an existing downside stress below the Covid-era observed P/E range, not a sourced forecast of owner-cash multiples.
  • DPLM-B2 —Test16.28% owner-cash margin from year 2, the present downside's normalization, instead of later recovery to 18.03%. Does inventory service create durable economics once scarcity rents fade?
  • DPLM-B3 —Test acquisition revenue price 1.995x against 1.6275x with acquired cash margin 15.75% unchanged. This isolates seller competition/price from target quality.

The issuer's Q3 transcript was reopened for this review. FY26 results are due 17 November 2026; FY26 profit, September debt, Peerless margins and deal earnings remain estimates until then. The 11 November correction removes the false claim that the annual report left the finance departure unexplained; the financial verdict is unchanged.

Shared-engine effects

Fixed saved quote GBP70.45; market timestamp 2026-11-04T17:15:00.000Z; valuation date 5 November 2026; fixed original exit calendar. Base before: 7.07% / 9.48% (5/10years). These are one-change sensitivities to the base, except named bundles; existing scenario probabilities are not revised or claimed as validated.

ClaimChange5-year base IRR10-year base IRR5-year effect10-year effect
DPLM-B1Exit16x0.75%6.46%-6.32pp-3.02pp
DPLM-B2Owner cash margin 16.28% from year 25.57%8.69%-1.50pp-0.80pp
DPLM-B3Acquisition price/revenue1.995x6.05%8.64%-1.03pp-0.84pp

Rebuttals

Bull response

5 November 2026. Written after independently frozen openings were exchanged. Every numbered bear claim is addressed below; original bull openings and sensitivities remain unchanged.

  1. Bear16× versus 22×: concede duration; reject arbitrary central 16×. A high tangible ROIC cannot by itself capitalise bought goodwill at the same return. My22× diagnostic's20% marginal return is illustrative blended productivity, not measured group new-money RONIC. Organic and acquisition capital must be separated. dplm-h126p5 and acquisition notes support acquired EBIT yields~13% before tax, while stage 6 after-tax deal cash is~10%. Both22× and 16× require explicit forward economics; historical P/E is not the same denominator.
  2. Bear16.28% owner-cash margin: partly rebut, partly concede. The issuer explicitly expects Peerless margin above acquisition level (dplm-q326-transcript, PDFp5), not a return to~30%. The present base already assumes 40% Peerless and a fall in owner-cash margin. But the exact starting~54% and eventual 40% are reconstructions, not disclosed target accounts. My stronger margin path belongs in upside; no evidence supports promoting 47–54% permanently. Bear16.28% is an adverse combination, not a newly observed normalization.
  3. Bull7.5% organic attacked: concede no complete group bridge. Datacentres~3% cannot alone generate group 7.5%; issuer ex-Peerless10% in the Q3 call is a useful current observation, not future proof.7.5% upside requires Controls/aerospace/defence and the rest of portfolio to persist together. Retain5→5.65% central until a full unit/customer bridge supports more. FY26 results 17 November must replace estimates. Conviction moderate on the business, low on a cheap stock at the current quote.

Bear response

5 November 2026, after independent openings were exchanged.

  1. Bull7.5% organic: possibility conceded, central upgrade rejected. Issuer Q3 ex-Peerless organic 10% is a favorable observation, and certified inventory service can grow. Datacentres at 3% of group cannot alone explain 7.5% sustained group growth; aerospace, defence, Seals and Life Sciences must jointly contribute. The bull concedes the complete bridge is missing. Retain the current 5→5.65% base rather than projecting one exceptional year (dplm-q326-transcript, PDFpp.2–4; sector ledger in 08-underwriting-plan).
  2. Bull higher structural Peerless margin: direction conceded, exact level unresolved. Management expects margin above the~30% acquisition level, supporting some structural improvement (dplm-q326-transcript, PDFp.5; dplm-peerless-rns, pp.1–2). It does not establish 47–54% forever. I concede the existing base already removes part of the windfall and that 16.28% is an adverse group margin, not an observed central level. Supplier economics and principal loss remain live counterarguments.
  3. Bull22/27x exit: blended productivity needs a denominator.20% blended marginal return cannot be inferred from 60% tangible organic returns when bought goodwill earns~10%. State the mix of new capital, not the share of reported growth (dplm-fy25-prelim funds flow/acquisition notes; matched stage 6 ledger). The bull concedes the 20% was illustrative. Likewise I concede 16x is a stress and not an independently derived central terminal value. The agreed current cash denominator differs from statutory P/E peers.
  4. Bear deal-price stress: bounded, not central. CDM~2.1x revenue is an observed expensive deal; LTM profit 40m/price310m and the multi-deal record support differentiated targets. I concede one transaction does not establish 1.995x for the whole future deal population. Retain it as competition/mix stress (dplm-h126, p.5; dplm-q326-transcript, p.2; acquisition notes).

No new numerical central input follows from this debate before 17 November FY26 results. The judgment should retain separate windfall and volume mechanisms, avoid double normalization, lower conviction in exact margins and publish the negative 16x stress alongside the favorable organic case. Main attacks on price/value survive without inventing a harsher base.

Judgment

Existing estimates receive no presumption merely because they are already in the model. Positive company evidence, the relevant outside view and the capital/funding bridge determine each verdict; neither arbitrary conservatism nor an unsupported favorable sensitivity replaces it. The evidence and reconstruction below explain numerical changes or explicit no-change conclusions claim by claim.

Contested claimVerdictEvidence/locatorReason and model action
bull advocate: DPLM-B1: cases.base.inputs.yearly.organicGrowthrejectdplm-q326-transcript PDF pp.2–5; dplm-peerless-rns pp.1–2; dplm-h126 sector tables/note10; dplm-fy25-prelim Life Sciences and acquisition notes. Ex-Peerless growth and aerospace backlog support base5.65%; 7.5% remains upside because some revenue carries shortage/price effects.Reconstructed the isolated proposed input/path from independent opening and shared engine, at frozen saved quote/date/horizons; source mechanism separated from unsupported numerical extrapolation.
bull advocate: DPLM-B2: cases.base.inputs.yearly.organicMarginrejectdplm-q326-transcript PDF pp.2–5; dplm-peerless-rns pp.1–2; dplm-h126 sector tables/note10; dplm-fy25-prelim Life Sciences and acquisition notes. Management expects margin above entry and below current; central partial normalization has direct support. Reconstructed54% target margin is not disclosed.Reconstructed the isolated proposed input/path from independent opening and shared engine, at frozen saved quote/date/horizons; source mechanism separated from unsupported numerical extrapolation.
bull advocate: DPLM-B3: cases.base.inputs.exitMultiplerejectdplm-q326-transcript PDF pp.2–5; dplm-peerless-rns pp.1–2; dplm-h126 sector tables/note10; dplm-fy25-prelim Life Sciences and acquisition notes. Low organic tangible-capital needs and service approvals support a conditional premium; 22x requires roughly 14 post-exit years at 10%growth/20%blendedreturn/8.5%requiredreturn.27x lacks independent runway support.Reconstructed the isolated proposed input/path from independent opening and shared engine, at frozen saved quote/date/horizons; source mechanism separated from unsupported numerical extrapolation.
bear advocate: DPLM-B1: Exit16xrejectdplm-q326-transcript PDF pp.2–5; dplm-peerless-rns pp.1–2; dplm-h126 sector tables/note10; dplm-fy25-prelim Life Sciences and acquisition notes. 16x is a coherent short-duration sensitivity, but approval/service economics and management-led normalisation support retaining conditional 22x, with duration unresolved rather than asserted as fact.Reconstructed the independent isolated stress at the same quote/date/horizons; do not treat stress size as a probability or a measured current fact.
bear advocate: DPLM-B2: Owner cash margin 16.28% from year 2rejectdplm-q326-transcript PDF pp.2–5; dplm-peerless-rns pp.1–2; dplm-h126 sector tables/note10; dplm-fy25-prelim Life Sciences and acquisition notes. Base annual margin already gives back scarcity rents; management says margin should remain above acquisition, supporting partial rather than full margin surrender.16.28% stays adverse.Reconstructed the independent isolated stress at the same quote/date/horizons; do not treat stress size as a probability or a measured current fact.
bear advocate: DPLM-B3: Acquisition price/revenue1.995xrejectdplm-q326-transcript PDF pp.2–5; dplm-peerless-rns pp.1–2; dplm-h126 sector tables/note10; dplm-fy25-prelim Life Sciences and acquisition notes. Higher prices may reduce future returns; matched deal population supports 1.6275x currently, not universal 1.995x. Keep seller-price stress visible.Reconstructed the independent isolated stress at the same quote/date/horizons; do not treat stress size as a probability or a measured current fact.

Retain existing coarse horizon-specific weights after reassessment: scenarios already represent these adverse/favorable operating mechanisms. Numerical odds are subjective, not verified frequencies; unresolved gaps prevent high conviction. No tuning to return.

Conviction

Low to moderate; valuable approvals/inventory service, unresolved Peerless normalization, current earning estimates and cohort sales. These are forward estimates with surviving attacks, not confirmed outcomes. Neither numerical calibration, a completed checklist nor passing software tests establishes investment skill. Reported facts stay separate from forward judgments, and adverse paths are not worst-case bounds.

What would change the view: 17 November FY2026: Peerless margin/organic growth, cash conversion, debt and acquisition proforma revenue/profit.

Exact inputs, isolated sensitivities, model hashes and same-price/date before/after returns.

Public source library

Primary filings, investor communications, and industry evidence.

primary

Diploma FY2025 preliminary results (year to 30 September 2025) ↗

Printed p.1 highlights; p.8 financial model; pp.12-19 sector reviews; p.20 income statement bridge; p.22 funds flow and acquisitions; pp.23-24 net debt; pp.27-30 statements; notes 2-15 pp.31-42 (segments p.32, geography p.33, net debt p.36, acquisitions pp.37-39, APMs pp.40-42).

Published Nov 18, 2025 · Reviewed Nov 3, 2026
primary

Diploma Annual Report and Accounts 2025 ↗

p.22-23 Controls businesses incl. Peerless 23% of sector revenue; remuneration pp.81, 89, 92-93; directors' report p.98 (shares in issue, substantial holdings); five-year record p.168. Rechecked pp.5 and 71 on 11 November: chair and nomination narrative explain the August 2025 CFO departure; issuer explanation is not independent assurance.

Published Dec 8, 2025 · Reviewed Nov 11, 2026
primary

Diploma half year results, six months to 31 March 2026 ↗

p.1 highlights and guidance; p.5 acquisitions (57 deals since 2019, 15 LTM deals c.GBP310m, c.GBP40m annualised profit); pp.7-11 sectors; pp.12-15 financial review, funds flow p.13, net debt p.15; statements pp.21-25; notes 2-13 (segments, acquisitions note 10).

Published May 19, 2026 · Reviewed Nov 3, 2026
primary

Diploma Q1 2026 trading update ↗

p.1: 14% Q1 organic growth; 4 acquisitions c.GBP75m; 8 deals in two quarters c.GBP130m with c.GBP20m annualised operating profit.

Published Jan 14, 2026 · Reviewed Nov 3, 2026
primary

Diploma Q3 2026 trading update (RNS) ↗

Nine months to 30 June 2026: 15% organic; FY26 guidance organic 14%, acquisitions +6%, margin c.26.5%, operating profit growth c.42%; CDM completed 25 June; FY results 17 November 2026.

Published Jul 16, 2026 · Reviewed Nov 3, 2026
primary

Diploma Q3 2026 trading update call transcript ↗

pp.1-3 CEO: CDM USD170m, c.USD80m revenue; FY27 to revert towards the financial model; Peerless growth moderating to c.10%, margin easing but structurally above acquisition level; defence 6-7% of revenue; datacentres c.3% of group; CFO: margin 'at the top end'.

Published Jul 16, 2026 · Reviewed Nov 3, 2026
primary

Diploma FY2024 preliminary results ↗

Funds flow table; note 11 acquisitions (Peerless GBP243.3m, pro forma GBP129.9m revenue / GBP59.9m adjusted operating profit; PAR GBP36.7m / GBP5.2m); organic reconciliation; CEO review (FY24 deals average 6x EBIT).

Published Nov 19, 2024 · Reviewed Nov 3, 2026
primary

Diploma Annual Report 2024 ↗

Five-year record p.186 (FY2020-FY2024), incl. FY2022 acquisitions GBP177.8m and FY2020 equity issue GBP189.8m. Date from PDF metadata; calendar says posted 6 December 2024.

Published Dec 5, 2024 · Reviewed Nov 3, 2026
primary

Diploma FY2023 preliminary results ↗

Funds flow (FY23/FY22); cash flow statement; note 11 acquisitions (T.I.E. GBP75.1m / pro forma GBP6.9m; DICSA GBP159.7m / GBP19.2m); organic growth 8%.

Published Nov 20, 2023 · Reviewed Nov 3, 2026
primary

Diploma FY2022 preliminary results ↗

Cash flow statement; note 13.4 free cash flow reconciliation (acquisitions GBP177.6m + fees 6.5 + deferred 7.1 + minorities 0.3 - disposals 13.7); note 12 acquisitions (R&G GBP99.1m); organic growth 15%.

Published Nov 21, 2022 · Reviewed Nov 3, 2026
primary

Diploma FY2021 preliminary results ↗

Underlying growth 12%; cash flow statement; free cash flow reconciliation; acquisition notes (Windy City Wire, 16 October 2020).

Published Nov 22, 2021 · Reviewed Nov 3, 2026
primary

Diploma Annual Report 2020 ↗

Five-year record p.112 (FY2016-FY2020 revenue, adjusted operating profit, adjusted EPS, margin). Publication date from the PDF creation date (27 November 2020).

Published Nov 27, 2020 · Reviewed Nov 3, 2026
primary

Diploma financial calendar ↗

Upcoming: 17 Nov 2026 preliminary results and final dividend; 13 Jan 2027 AGM and Q1 update; 18 May 2027 half year.

Published Nov 3, 2026 · Reviewed Nov 3, 2026
market-data

Yahoo Finance market data for DPLM.L ↗

Last price 7,265p (2 November 2026 close); 52-week range 4,970-7,980p; 3-month average daily volume c.651k shares; 12-year monthly closes used for the trailing P/E history. Market data, not issuer disclosure.

Published Nov 3, 2026 · Reviewed Nov 3, 2026
market-data

Yahoo Finance GBP exchange-rate history ↗

Average GBP/USD 1.3424 (Apr-Sep 2025) vs 1.3431 (Apr-Sep 2026); GBP/EUR 1.1654 vs 1.1613; GBP/CAD 1.8527 vs 1.8694; GBP/AUD 2.0719 vs 1.8976.

Published Nov 3, 2026 · Reviewed Nov 3, 2026
market-data

Yahoo Finance peer quotes (trailing statutory P/E), 2 November 2026 ↗

Trailing P/E: Fastenal 42.7, Grainger 35.1, MSC 30.1, IMCD 26.9, RS Group 23.1, Wesco 20.8, Bossard 19.4, Bunzl 19.2, Halma 36.1. Statutory earnings, so acquisitive peers' amortisation distorts comparisons. Analyst forward estimates are not used.

Published Nov 3, 2026 · Reviewed Nov 3, 2026
primary

RS Group half-year results to30September2026 ↗

PDF pp.1-9 operating/demand review; p.12 cash and inventory; p.30 APM cash reconciliation. Read issuer PDF text via web; local download403 and screenshot cache miss. Broader industrial-distribution evidence, not Diploma segment measurement.

Published Nov 5, 2026 · Reviewed Nov 7, 2026
competitor-primary

Spirax Group trading update for four months to 31 October 2026 ↗

Original complete two-page content: industrial MRO, semiconductor equipment and biopharm orders; trading, financial position and unchanged outlook. End-market context, not Diploma sales, margins or acquisition returns.

Published Nov 11, 2026 · Reviewed Nov 11, 2026
primary

Diploma12November block-listing application ↗

Full RNS body, excluding the host AI summary: application for249,058 ordinary5p shares under2020 Performance Share Plan; expected admission16November. Not an observed exercise or updated issued-share total.

Published Nov 12, 2026 · Reviewed Nov 12, 2026